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Atherosclerotic cardiovascular disease (ASCVD), also known as coronary artery dis-
ease (CAD), is one of the leading causes of death in the world.[22] A consensus has
been reached that the main cause of ASCVD are low-density lipoproteins (LDL).[16]
ASCVD develops in the innermost layer of the coronary artery wall (intima). Once
LDL particles enter the wall, they are retained, modified, and accumulate there.[35]
There are several well-known risk factors of ASCVD, among which obesity, smoking,
hypertension and LDL cholesterol concentration in the plasma.[35] A novel approach
to assessing the risk of ASCVD however suggests that not only the concentration, but
also the susceptibility of LDL particles to aggregate plays a role in ASCVD. [35] This
makes investigating LDL aggregation particularly important.
This thesis studies LDL aggregation of one particular cohort - obese people who un-
derwent bariatric surgery, a standard weight-loss procedure. The goal of the thesis is
to investigate whether bariatric surgery affects LDL aggregation, the structure of LDL,
and clinical parameters of the patients. In addition, it aims to establish whether LDL
aggregation in bariatric surgery patients is correlated with the structure of LDL and
selected clinical parameters.
The thesis is thus built upon four main points. First, it focuses on creating a nonlinear
mixed-effects model of LDL aggregation and obtaining a single quantitative measure
for it. Second, it investigates whether there is a significant difference in LDL aggre-
gation in patients before and after bariatric surgery. Third, it studies correlations of
LDL aggregation and the core and surface lipids, contained in LDL, known as the LDL
lipidome, as well as clinical data of the patients. Fourth, it investigates whether there
is a significant difference in the LDL lipidome lipids and clinical parameters in the
patients before and after the operation.
The results indicate that bariatric surgery does not appear to affect LDL aggregation.
However, it appears to affect the surface structure of LDL. In addition, patients exhibit
improvement of blood pressure, glucose levels, as well as BMI, after the operation.
Keywords: LDL, aggregation, lipid, atherosclerosis, bayesian, mixed-effects,
nonlinear, model, correlation, bariatric, surgery
Language: English
2
Acknowledgements
First, I would like to thank the lead of the Atherosclerosis group at Wihuri
Research Institute, Doc. Kati O¨o¨rni for the opportunity to be part of this
project, as well as her patience and ability to explain complex biochemistry to
a statistician. This project sparked my curiosity and helped me discover my
passion for biostatistics. I would also like to thank my supervisor Doc. Lasse
Leskela¨ and my advisor Matti Pirinen for their patience and help. I would
also like to thank the whole Stan community for their tireless dedication to
promote Bayesian statistics and their readiness to be helpful.
Last but not least, I would like to thank my friends and family for helping
me keep my chin up and making me laugh, even when project work was not
going smoothly.
Espoo, August 14, 2019
Mihaela Mihaylova
3
Abbreviations and Symbols
Abbreviations
LDL Low-density lipoprotein
ASCVD Atherosclerotic Cardiovascular Disease
CAD Coronary Artery Disease
DLS Dynamic Light Scattering
FDR False Discovery Rate
FWER Familywise Error Rate
LOO-CV Leave-One-Out Cross-Validation
ELPD Expected Log-Pointwise Predictive Density
CLT Central Limit Theorem
PPC Posterior Predictive Check
MAE Mean Absolute Error
Symbols
N(-,-) Normal distribution
Gamma(-,-) Gamma distribution
X set of explanatory variables
x explanatory variable
y observed response
p(x) probability distribution function
p(x,y) joint probability distribution function
p(x|y) conditional probability
E expected value
θ model parameters
θˆ estimator for model parameters
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µ mean
σ standard deviation
g(.) link function
η linear predictor
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Chapter 1
Introduction
Cardiovascular diseases are the major cause of death in developed and an
increasing cause of death in developing countries. [18] Thus their cause,
treatment, and prevention have become a focus of research for many. The
role of LDL in ASCVD, one of the most spread cardiovascular diseases, has
been of particular interest. Based on a large body of evidence from clinical,
epidemiological, and genetic studies, an agreement has been reached among
researchers that LDL is the main cause of ASCVD. [16]
LDL particles can efficiently cross the innermost layer of the coronary artery,
the coronary intima. They accumulate at the sites of the intima, which
are prone to plaque formation, and are turned into plaque. [16] If high
concentration of LDL in the plasma is maintained for a long period of time,
the amount of plaque increases, resulting in ASCVD, characterized by a
decrease in blood flow to the heart muscle, and the arterial walls getting
more rigid and prone to rupture. If the plaque in the arterial wall ruptures,
the platelets start clumping and form a blood clot, which could potentially
lead to complete blocking of the artery, which means that part of the heart
is deprived of oxygen, resulting in a heart attack.
Recent studies, however, suggest that not only the concentration of LDL in
the plasma, but also the quality of LDL might play a role in CAD. And,
more precisely, LDL’s susceptibility to aggregate may be used as a predictor
of future CAD deaths. [35] One group of people who are particularly at risk
of ASCVD are obese people. Obesity is considered a major risk factor for
ASCVD, as it is associated with other major risk factors, leading to ASCVD,
such as hypertension, hyperglycemia, and hypercholesterolemia. [25]
This thesis focuses on studying the LDL aggregation of patients who
underwent bariatric surgery —an operation which helps obese people lose
weight, by making changes to their digestive system. [32] Available before-
and after-operation data of the patients is used. There are three main types
9
CHAPTER 1. INTRODUCTION 10
of data considered —LDL aggregation data, LDL lipidome data —the types
of lipids found in the surface and core of LDL, as well as patients’ clinical
data. These are split into four datasets —an LDL aggregation dataset, an
LDL surface lipids dataset, an LDL core lipids dataset, as well as a set of
clinical data.
The goal of the thesis is to investigate whether bariatric surgery affects
LDL aggregation, the structure of LDL, and clinical parameters of the pa-
tients. In addition, it aims to establish whether LDL aggregation in bariatric
surgery patients is correlated with the structure of LDL and selected clinical
parameters. The exact questions which this thesis aims to answer are given
below:
• Is there a significant difference in LDL aggregation of bariatric patients
before and after the operation?
• Are there any significant changes in the structural lipids of LDL parti-
cles of the bariatric patients before and after the operation?
• Are there any significant correlations between LDL aggregation and
LDL structural lipids before and after the operation?
• Are there any significant changes in the clinical parameters of the
bariatric patients before and after the operation?
• Are there any significant correlations between LDL aggregation and
clinical parameters before and after the operation?
• Are there significant correlations between change of LDL aggregation
and change in the structural lipids and clinical parameters of the patients,
as a result of the operation?
The steps taken towards achieving the goal of the thesis are described in
the following chapters. In Chapter 2, the necessary background knowledge
on LDL, LDL aggregation, and measuring LDL aggregation is provided. In
Chapter 3, we look more closely at the work that has been done so far on the
topic. And more precisely, we focus on the paper by Ruuth et al[35] which
suggested using LDL aggregation as a potential diagnostic for ASCVD. The
similarities and differences of the modeling approaches of LDL aggregation
in this thesis and the original paper are described. In Chapter 4, the datasets
available for our study are described. In addition, the chapter describes the
necessary data preparation done, which allows us to get a clearer idea of the
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nature of the data and thus helps us identify the best steps to take, in order
to answer the posed research questions. Furthermore, this chapter provides
a brief review of the basics of Bayesian inference, a description of nonlinear
mixed-effects models, as well as the mathematical formulation of the LDL
aggregation model. We also discuss methods for model checking and model
comparison, as well the statistical tests we use to obtain answers of the re-
search quesitons.
Chapter 5 provides results of the tests conducted on the available data. Chap-
ter 6 then provides interpretation of the results obtained and their implica-
tions. It also discusses some limitations of the work done in the thesis and
ways to potentially improve it in following studies. Chapter 7 concludes the
thesis by providing a brief summary of the work done.
Chapter 2
Background
The goal of this chapter is to provide the necessary background in biology, in
order for the reader to be able to understand the research problem at hand,
as well as some data preparation and modelling decisions. We first briefly
discuss the nature, structure, and purpose of lipoproteins in the body, as
well as the types of lipoproteins that can be found in humans. We then
introduce the low-density lipoprotein (LDL), which is at the core of the
research problem in this thesis. We focus on the structure of LDL and its
role in the pathophysiology of atherosclerosis. In addition, the steps taken
to initiate and measure LDL aggregation are discussed. We then end the
chapter with a brief introduction to Dynamic Light Scattering (DLS) - the
method used for measuring LDL aggregation, as this gives some insights in
the data cleaning process described later on.
2.1 Lipoproteins
Lipoproteins are complex particles which consist of lipids, which are insoluble
in water, and proteins, whose purpose is to transport these lipids in the body.
2.1.1 Lipids
Lipids (also known as fats) are a diverse group of organic molecules, which
are poorly soluble in water. Lipids can be polar amphipathic or nonpolar
(completely insoluble in water). Polar lipids are poorly soluble in water be-
cause they are amphipathic, which means that they have both hydrophilic
and hydrophobic regions in the same molecule. Some of the more impor-
tant nonpolar lipids are cholesterol and triglycerides. [7] Triglycerides are
important for the body as they serve as a source of energy.[37] Cholesterol
12
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is a crucial component of cell membranes and is used for making molecules,
which are essential to the body, such as hormones, fat-soluble vitamins, and
bile acids which help in digestion.[1]
2.1.2 Proteins
Proteins are macromolecules, which consist of long chains of smaller units
attached to one another, called amino acids. Proteins perform a wide range
of functions in the human body, such as antibodies, structural components,
transport and storage, and others. [8]
2.1.3 Structure of Lipoproteins
Since essential lipids such as cholesterol and triglycerides are insoluble in wa-
ter, they need to be transported within the body in lipoproteins. Lipopro-
teins are compound particles, containing both lipids and proteins whose main
purpose is the transport of lipids in the body. [14]
Figure 2.1: Structure of a lipoprotein, Source: [15]
Lipoproteins have a hydrophobic core which contains cholesterol esters
and triglycerides. Their surface structure consists of free cholesterol, phos-
pholipids, and apolipoproteins, which facilitate the formation and function
of lipoproteins. [15]
2.1.4 Lipoprotein Classes
Plasma lipoproteins are divided into seven classes, based on their size, lipid
composition, and types of apolipoproteins. [15] The seven classes are, as
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follows: chylomicrons, chylomicron remnants, very-low-density lipoproteins
(VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins
(LDL), high-density lipoproteins (HDL), Lipoprotein-a (Lip-a).
These perform different functions in the body, however, for the sake of
brevity, we would not go into more detail. The figure below shows the types
of lipoproteins with their size ranges.
Figure 2.2: Classes of lipoproteins, Source: [15]
The majority of lipoproteins in the plasma, including LDL, which is in the
focus of this thesis, are pro-atherogenic. HDL is the only anti-atherogenic
plasma lipoprotein. The pro-atherogenic lipoproteins promote the devel-
opment of atherosclerosis - the underlying condition for ASCVD. We now
focus on the structure and function of LDL, and the way it contributes to
atherosclerosis.
2.2 LDL
Low-density lipoproteins, or LDL, are derived from VLDL and IDL, and
have very high content of cholesterol. LDL is, in fact, the main carrier of
cholesterol in the circulation.[15] An LDL particle consists of one molecule
of Apo B-100 protein, triacylglycerol (also known as triglyceride) and es-
terified cholesterol in the core, and phospholipid monolayer and unesterified
cholesterol forming the surface.[15] A figure showing the structure of an LDL
particle is given below.
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Figure 2.3: Structure of an LDL lipoprotein, Source: [11]
LDL particles vary in size and density. High numbers of small LDL
particles present in the plasma are usually associated with obesity and in-
flammatory states. In addition, small LDL particles are supposed to be more
pro-atherogenic. [15]
2.3 Role of LDL in Atherosclerosis
2.3.1 What is Atherosclerosis?
Atherosclerosis is the underlying reason for ASCVD.[22] It is a condition
in which plaque builds up inside the arteries. The plaque consists of fat,
cholesterol, calcium and other substances found in the blood. As the plaque
buildup expands, it becomes more difficult for oxygen-rich blood to reach
the heart and other body parts. This can result in heart attack, stroke, or,
potentially, death. [31] For this reason, atherosclerosis has been a subject of
interest of many researchers in the past decades. Based on evidence from a
large amount of various clinical, epidemiological, and genetic studies, con-
sensus has been reached among researchers that LDL is the main cause of
atherosclerosis. [16]
2.3.2 How Does LDL Contribute to Atherosclerosis?
An artery wall consists of two main layers - intima and media. The inner
layer, the intima, consists of a single layer of endothelial cells - the endothe-
lium, and internal elastic lamina. [22]
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Figure 2.4: Structure of a normal artery, Source: [22]
The endothelium is prone to activation, due to inflammation, and damage
caused by risk factors, such as high blood pressure, smoking, and obesity.[22]
Once activated or damaged, the endothelium allows the entry of LDL and
monocytes into the artery wall.[22] Once entering the artery, monocytes dif-
Figure 2.5: An artery wall with a damaged endothelium, Source: [22]
ferentiate into macrophages which take up the LDL particles and become
foam cell macrophages. As a result, lesions, known as ”fatty streaks” are
formed. This is considered to be the onset of atherosclerosis.[22]
Fatty streaks may be precursors of larger atherosclerotic plaques, but they
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Figure 2.6: Fatty Streak Formation, Source: [22]
may also regress. A progression of fatty streaks is caused by the formation
of a necrotic core and a fibrous cap. [22]
Figure 2.7: Formation of Stable Atherosclerotic Plaque, Source: [22]
Foam cells macrophages, full of LDL, start dying and release their con-
tents, which helps in the formation of a necrotic core. The released content
of the cytoplasm of the foam cells leads to the accumulation of extracellular
lipids which induce inflammation. In addition, vascular smooth muscle cells
migrate from the media layer into the intima and form a fibrous cap around
the necrotic core. [22] The plaque could then grow and change. A plaque
which has a large necrotic core, high content of inflammatory cells,and thin
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fibrous cap is unstable, and is very prone to rupture. [22]
Figure 2.8: Unstable Atherosclerotic Plaque, Source: [22]
If the unstable plaque ruptures, platelets in the blood start forming a
blood clot (thrombus). The supply of oxygen-rich blood to the heart is thus
cut off, resulting in a heart attack and, potentially, death. [22]
Figure 2.9: A Ruptured Unstable Plaque Causes Thrombus, Source: [22]
The rupture of the plaque is sudden, which makes it very dangerous, as
the reaction time for treating the condition is fairly short. Thus, developing
methods to assess a person’s risk of atherosclerotic death is important, as it
allows taking steps towards its prevention.
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2.3.3 LDL as a Predictor of Cardiovascular Atheroscle-
rotic Deaths
As mentioned earlier, high concentration of LDL is the main factor for
atherosclerosis, however, the quality of LDL is also thought to be a contributor.[35]
In this context, the study by Ruuth et al [35] defines the quality of LDL as
its susceptibility to aggregate in the presence of the human recombinant
secretory sphingomyelinase enzyme. In the study by Ruuth et al, the sus-
ceptibility of LDL to aggregate in the presence of the enzyme was predictive
of future atherosclerotic deaths in patients with ASCVD, independently of
traditional risk factors. [35]
2.4 Measuring LDL Aggregation
Having discussed the importance of LDL in predicting atherosclerotic deaths,
it is now good to have a look at how LDL aggregation is measured, as this
would allow us to better understand our data and be able to identify any
errors in the dataset.
The process of measuring LDL aggregation consists of several steps:
1. Obtaining blood samples from the subjects of interest
2. Separating the blood cells from the plasma using centrifugation
3. Separating the LDL particles from the plasma using ultracentrifugation
[35]
4. Human recombinant secretory sphingomyelinase enzyme was added to
the isolated plasma LDL [35]
5. Once the LDL particles start aggregating, the radius of the aggregates is
measured throughout time, using Dynamic Light Scattering (DLS).
It is good for the reader to get a brief overview of how Dynamic Light
Scattering works, as it would put into context some of the decisions we make
later on when dealing with problematic data points. In addition, it could
potentially be helpful to any future reader who is on the statistics side of a
biochemistry-related project making use of DLS.
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2.4.1 Dynamic Light Scattering
In a solution, macromolecules are hit by the molecules of the solvent, lead-
ing to random motion, known as Brownian motion.[44]The moving macro-
molecules scatter light, with their motion adding randomness to the phase
of the scattered light, so that when the light from several particles is added
together, it results in a destructive or constructive interference. This, in
turn, leads to time-dependent intensity fluctuations of the scattered light.
[44] In DLS, the time-dependent fluctuations of the scattered light are mea-
sured by shooting a laser through the solution and registering the diffusion
of the macromolecule using a fast photon counter.[44] The registered fluctua-
tions are directly related to the macromolecule’s rate of diffusion through the
solvent, which is, in turn, related to the hydrodynamic radius of the macro-
molecule. [44] So, in effect, what DLS measures is the hydrodynamic radius
of the macromolecule - that is, the radius of perfectly spherical particle which
diffuses light at the same speed as the macromolecule of interest. [33]
Figure 2.10: Basic Dynamic Light Scattering measurement system, Source:
[33]
The measurements of scattered light in DLS are made over a short time
period, allowing the instrument to monitor the particles’ movement. As
the particles move, the intensity of the scattered light fluctuates over time.
Smaller particles move faster than large particles, thus resulting in faster
fluctuations. The generated intensity trace is then used to generate an inten-
sity autocorrelation function. [33] The autocorrelation function is essentially
used to describe how long a particle stays at the same position in a solution.
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Figure 2.11: Comparison of Intensity and Correlation plots of small and
large particles [33]
As one can see, the upper part of the autocorrelation graph is roughly
constant, which indicates the particle being in the same position at time t
+ ∆t, as it was at time point t. The exponential decay which follows means
that it changes its position with time. When the particle gets to a position
where there is no similarity with its initial position, the correlation function
goes flat again. The bottom flat part of the correlation graph is called a
baseline. [33]
The reason why this is important, is because it is one of the criteria for
determining the quality of measurements. One can set a certain baseline and
if this is not reached within a predetermined time frame, the measurement
is discarded. The reasoning behind this is that if the correlation function is
decreasing too slowly, this means that the molecule whose size we are trying
to measure is too big, which can result in inaccurate measurements. [12]
Now that we have provided the necessary biological background to un-
derstand the research question, we now continue to discussing the paper by
Ruuth et al, which served as a main inspiration for this thesis.
Chapter 3
Related Research
In this chapter we focus on the paper of Ruuth et al [35], which studies LDL
aggregation and suggests it is predictive of future atherosclerotic deaths.
The study introduces the idea that not only the concentration, but also
the quality of LDL contributes to ASCVD [35]. In this context, the ”qual-
ity” of LDL is defined as its susceptibility to aggregate in the presence of
the enzyme hrSMase. In the experiment described, LDL is isolated from the
plasma of participants from several groups, including healthy volunteers, par-
ticipants in a health examination survey, participants with CAD in a study
about the risk factors and genetics of heart disease, as well as a dietary study.
[35] Next, the enzyme hrSMase is added to the LDL samples, which causes
LDL particles to start aggregating. The size of the aggregates is then mea-
sured in time, using DLS. The data is then used to fit a model to describe
LDL aggregation in time.
In order to describe LDL aggregation with a single number, the authors
use the size of LDL aggregates at the 2-hour time point. The reason for using
this specific time point is because it was established to clearly separate sub-
jects whose LDL aggregates slowly from subjects whose LDL aggregates very
fast. The size at the 2-hour time point is also found to be strongly positively
correlated with the inflection point of the curve fitted. In addition, LDL
aggregation is also found to depend on the structure of the LDL particles.
And, most importantly, the presence of aggregation-prone LDL is found to
be associated with future CAD deaths, independently from other traditional
risk factors. [35]
It is now worth drawing parallels, as well as establishing the differences
between the Ruuth et al study and this thesis project. This thesis can be
seen as a follow-up study of the this paper, with focus on one particular study
population - bariatric surgery patients.
To start with, while the Ruuth et al study uses LDL aggregation data
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from several different studies, this thesis is based only on data from bariatric
surgery patients. Additionally, while the subjects from the original study can
be categorized in several different groups, the data in this thesis is paired -
before- and after-operation data of the same patients, which allows for study-
ing changes in LDL aggregation, the LDL lipidome, and clinical parameters,
as a potential result of the operation.
Additionally, the amount of LDL aggregation data in the original study is
significantly larger than the amount of data used in this thesis, which makes
it harder to develop a reliable, generalizable model for LDL aggregation of
bariatric surgery patients in this project.
In addition, both studies use the predicted values of the size of LDL
aggregates at time point t=2h.
Moreover, while both studies look into correlations of LDL aggregation
with structure lipids in the LDL lipidome, this thesis also looks into cor-
relations between LDL aggregation and clinical parameters of the patients
studied.
As to modelling LDL aggregation, both the original study and this thesis
use a slightly modified generalized logistic regression, also known as Richard’s
curve. This type of curve was chosen because the S-shape it describes is very
similar to the shape which data points of LDL aggregation, taken in time,
form. Additionally, this curve was originally developed by Richards [34] to
model growth, and is widely used in biology. Both works use this curve as a
basis for developing a nonlinear mixed-effects model.
Unlike the original study, which uses the Maximum-Likelihood Estima-
tion approach to obtain estimates for the model parameters, this thesis uses
the Bayesian modelling approach. One of the reasons for this is because
Bayesian modelling allows for incorporating previous knowledge about the
parameters through the priors. In addition, it allows for more adequately
handling the uncertainty around both parameter estimates and values pre-
dicted by the model.
In addition, while the original study assumes a normal distribution for
the response variable, which suggests that the variance of all measurements
of LDL is the same, in this thesis we choose a Gamma distribution. This
allows us to take into account the growing uncertainty of the measurements
of LDL aggregates as the values grow larger.
Having covered the basic similarities and differences of the two studies,
we now proceed to a discussion of the thesis’ methodology.
Chapter 4
Methods
4.1 Data
As already mentioned, this project focuses on studying the LDL aggregation
of bariatric surgery patients and its potential correlations with LDL struc-
tural lipids, as well as various clinical parameters, collected by the patients.
The data was gathered from 33 individuals who underwent bariatric surgery,
however, since some of them did not show up for an after-operation follow-
up, some of them were excluded, resulting in the final number of patients
studied to be 28.
Blood samples and some clinical measurements were taken twice - before
the operation, and 6 months after the operation. The blood and plasma
samples were then tested, which generated part of the data. The other part
were the clinical measurements taken from the patients.
Below we provide details about the available datasets - specifics of the
data collection, data cleaning, as well as explanation of the variables they
contain.
4.1.1 LDL Aggregation Dataset
As mentioned earlier, the original experiment included 33 individuals who
were about to have bariatric surgery. Blood samples were taken immediately
before (”BEFORE”-state) and 6 months after the operation (”AFTER”-
state). However, in the end some of the subjects did not undergo the surgery
or did not attend the six-month follow up. Thus, we only had samples
available from their ”BEFORE”- state.
All available samples were analyzed using DLS, as described earlier. How-
ever, since for some subjects there was only ”BEFORE”-data available, these
were excluded, as we wanted to focus solely on analysis of the differences of
24
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”BEFORE”- and ”AFTER”- states, and keeping these would have been an
unnecessary complication. In the end, there were 28 subjects left, for whom
before- and after-operation samples were available.
For each subject sample repeated measures of the hydrodynamic radius
of LDL aggregated particles were taken throughout a roughly 4-hour time
frame. This time frame, as well as the number of measures taken during it,
slightly varied for each sample, due to the way in which the DLS instrument
works.
Once the DLS data was obtained it was filtered. Only particles which
reached a baseline < 1.01 were left. What this means in practice is that
the measurements of LDL aggregates with very large radius were excluded,
as these are supposed to have considerably more uncertainty, compared to
smaller particles.
In addition, a second filter was applied, which excluded particles whose
actual correlation function differed significantly from the correlation function
fit, measured as sum of squares (SOS). [42]The limit we set was SOS < 100.
Again, the goal of this filter is to exclude particles with large fluctuations in
their intensity autocorrelation, which is usually a sign of a problem.
In addition, the recommended upper limit of hydrodynamic radius of par-
ticles that can be measured accurately by the instrument used, was 1000nm.
[43] However, following this recommendation strictly would have left us with
very few data points per sample, which would have made modelling LDL
aggregation very difficult and, potentially, highly inaccurate. So at first the
model we chose was fit with all the data, which resulted in very large stan-
dard errors for the predictions made. So several smaller cut-off points for
the measurement values were tried out. Eventually, it was decided that only
measurements with values of the radius up to 1500nm were to be used. This
value was chosen, as it is close to the recommended value of 1000nm, and
yet large enough to allow a reasonable amount of data points per sample.
The final LDL aggregation data set contained 368 measurements in to-
tal. These measurements were generated from DLS analysis of 56 samples,
taken from 28 individuals - 28 samples taken at the ”BEFORE” state, and
28 samples taken 6 months after the operation - the ”AFTER” state. The
final data set contained 5 variables:
• Pat - A nominal variable. It contains the id of each patient. This means
that two samples in the dataset had the same patient id - a before- and after-
sample taken from the same patient.
• Sample - A nominal variable. It contains id for each sample taken
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• Time - A continuous variable. Contains the time points at which mea-
surements of the LDL radius were taken. For each sample the first value of
time is 0. And the rest of the time points are relative to it, representing the
time which has passed from time point t=0.
• LDL - A continuous variable. It contains the values of the hydrodynamic
radius of the LDL aggregates.
• Category - A categorical variable. It contains two values ”B” and ”A”,
which denote the state in which the sample was taken, respectively before
and after the operation.
4.1.2 LDL Surface Lipids Dataset
As mentioned earlier, LDL consists of a surface and a core. This dataset
contains measurements of the surface lipids present in the LDL particles of
the tested subjects, before the onset of LDL aggregation. Again, the data
was gathered by first isolating LDL from the plasma and then conducting the
analysis of the surface lipids in lab settings. The measure used for the surface
lipids is molar percentage, which in this case is defined as the amount of a
certain lipid in the surface (measured in moles), divided by the total amount
of lipids in the whole surface. The number of surface lipids measured was
49. These constituted 4 main groups:
• LysoPC - Lysophosphatidylcholines
• PCalkyl - Phosphatidylcholine alkyls
• PC - Phosphatidylcholines
• SM - Sphingomyelins
As this is beyond the scope of this thesis, the nature of these will not be
explained further. As to data cleaning, the data for subjects with only before-
operation data available were excluded, as in the first dataset. Two of the
surface lipids were excluded, as they had a significant number of 0 values
across samples - over 30%. The non-zero values for these lipids were, on
average, less than 0.5%. The molar percentages of the surface lipids which
were kept were not recalculated to add up to 100% per sample. The rest of
the lipids had no value 0, with the exception of two lipids, each of which had
four 0 values across samples, but these were kept.
CHAPTER 4. METHODS 27
Thus, eventually, the dataset consisted of 48 variables - a sample id and 47
surface lipids which can be found in the surface structure of an LDL particle.
4.1.3 LDL Core Lipids Dataset
This dataset originally contained 30 core lipids - cholesterol esters. As it is
beyond the scope of this thesis, we will not discuss the nature of these further,
it is sufficient to know that they can be found in the core of an LDL particle.
The measure used for the core lipids was molar percentage of the core. To
start with, we removed the subjects, for whom we only had before-operation
data. Next, as most of those lipids contained more than 50% of zero values,
these lipids were removed. The sum of the non-zero values for these lipids for
each sample were, on average, less than 0.5% of the total 100% per sample.
As in the previous dataset, the molar percentages of the lipids which were
kept were not recalculated to add up to 100% for each sample.
Eventually, the dataset contained 8 variables - a sample id and 7 LDL
core lipids.
4.1.4 Clinical Dataset
The last dataset contained clinical measurements of the patients taken before
and after the operation. As not all of those were relevant to our study, some
were removed. In addition, only the data of subjects which had both before-
and after-operation data were kept. Eventually, the dataset contained 11
clinical parameters for the patients:
• Sample: A nominal variable. Denotes the sample id.
•Weight: A continuous variable. Weight of a patient (in kg)
• BMI: A continuous variable. Body Mass Index of a patient (kg/m2)
• RRSys: A continuous variable. Average systolic blood pressure of a pa-
tient (in mmHg - millimeters of mercury [30])
• RRDia: A continuous variable. Average diastolic blood pressure of a
patient (in mmHg - millimeters of mercury)
• Pulse: A discrete variable. Pulse of a patient (bpm - beats per minute)
• ogtt0: A continuous variable. Glucose level at time 0. (in mmol/L)
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• ogtt30: A continuous variable. Glucose level at 30 mins. (in mmol/L)
• ogtt60: A continuous variable. Glucose level at time 60 mins. (in mmol/L)
• ogtt120: A continuous variable. Glucose level at time 120 mins.(in
mmol/L)
• HbA1C: A continuous variable. Average blood glucose levels (in mmol/-
mol)
The variables ogtt0, ogtt30, ogtt60, and ogtt120 contain values of the Oral
Glucose Tolerance Test (OGTT). This test is used to determine the body’s
ability to metabolize the intake of sugar. When the test is done, the pa-
tient is asked to ingest a glucose drink, and then their blood glucose level is
measured at several time intervals. Problems with metabolizing sugar might
indicate that the person suffers from diabetes melitus. [3] And since diabetes
is one of the risk factors for atherosclerosis, we are interested in these clinical
parameters of our test subjects.
As a contrast, HbA1C measures average blood glucose levels, and not
the body’s short-term ability to metabolize sugar. This clinical parameter is
also used as an indicator for diabetes complications [4], which also makes it
a quantity of interest for our study.
4.2 Theoretical Background
Before continuing to discussing and comparing the models we built for LDL
aggregation, we are going to briefly review some basic theory, related to
Bayesian inference and nonlinear mixed-effects models, which is necessary to
understand the modelling decisions we make later on. In addition, we discuss
leave-one-out cross-validation (LOO-CV), the criterion we use to compare
the two models built for LDL aggregation. Additionally, we briefly discuss
paired t-test and Wilcoxon rank-signed test, used for testing the differences of
the before-after paired values of some variables of interest, as well as Spear-
man correlation, which we later on use for studying correlations between
our variables of interest. In addition we include a brief discussion of the
Benjamini-Yekutieli multiple testing adjustment, used to account for testing
several hypotheses at the same time. We conclude the chapter by discussing
brms - the R package used for fitting our models.
It is worth pointing out that in this subsection we only provide brief
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overviews of the concepts and tests used, rather than in-depth discussion. If
needed, the reader could find more detailed explanations of the concepts in
introductory texts on Bayesian statistics, as well as how and why the tests
we use work, in introductory texts on applied statistics.
4.2.1 Basics of Bayesian Statistics
In this subsection we are going to briefly discuss several key concepts of
Bayesian statistics. We also include the frequentist view on some of these
concepts to serve as a contrast, in order to create some intuition and enhance
the understanding of readers who have only been exposed to the frequentist
take on statistics.
4.2.1.1 Bayesian Probability
The first important concept we would like to review is the concept of prob-
ability. Let us start with the frequentist view on probability.
The frequentist definition of probability is based on considering the out-
comes of an experiment which is repeated many times, at least in theory.
The probability of an outcome is defined as the limit of the frequency of
occurrence of the outcome, considering all possible outcomes, as the number
of repetitions of the experiment grows very large. [27]
On the other hand, Bayesians define probability as a quantification of
one’s personal belief in a certain outcome. This is, how certain a person is,
that a certain outcome would take place. Thus, in the context of Bayesian
statistics, probability is fundamentally subjective. [27]
4.2.1.2 Bayesian Inference
Another major difference between frequentists and Bayesians is their ap-
proach to statistical inference. Statistical inference is the process of drawing
conclusions about a population, based on observed data. Drawing conclu-
sions can be done by estimating parameters and predicting new observations.
One example of conducting statistical inference is fitting a parametric model
to data. Let us now discuss how this is done in both frequentist and Bayesian
inference.
Frequentist inference considers model parameters as unknown fixed val-
ues, which can be obtained through calculations, based on the observations.
The uncertainty around the obtained point estimates for the parameters is
expressed through confidence intervals. A confidence interval around a point
estimate can only be interpreted as a sequence of repeated similar inferences
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about said estimate. [20] One downside to using the frequentist approach to
estimating model parameters is that the interpretation of confidence intervals
is not very intuitive.
In contrast, while in Bayesian inference parameters are in principle con-
sidered fixed, the uncertainty about them is modelled by probability distribu-
tions, rather than confidence intervals. [27] This results in Bayesian inference
conclusions being presented as distributions for the model parameters and
predictions, rather than point estimates, as it is in frequentist inference. One
advantage of the Bayesian approach is that one can incorporate some prior
knowledge about the value of a parameter, before even considering the data.
This prior knowledge can be based on, for example, previous experiments,
involving the same type of data, or reflect a personal belief, which makes it,
to a large extent, subjective. This prior knowledge about the parameters can
then be updated with information obtained from the observed values, which
allows for better estimates of the parameters. But, in order to explain how
exactly this is done, let us quickly focus on the basis for Bayesian statistics
- Bayes’ rule.
4.2.1.3 Bayes’ Rule
Bayes’ Rule, is the basis for Bayesian inference. Bayes’ rule is derived by
expressing the joint probability distribution of two random variables x, y in
two different ways:
p(x, y) = p(x|y)p(y) (1)
where
p(x,y) - joint probability distribution of x and y
p(x|y) - conditional probability - the probability of x occurring, given that
y has occurred
p(x) - the probability of x occurring, independently from y
and also
p(x, y) = p(y|x)p(x). (2)
Combining these two
p(x|y)p(y) = p(y|x)p(x) (3)
And rearranging them results in the Bayes’ rule:
p(x|y) = p(y|x)p(x)/p(y) (4)
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As mentioned already, Bayes’ rule is relevant because it is at the heart of how
parameter estimation is done in Bayesian inference. Let us first demonstrate
how this is done for a single-parameter model.
Let θ be the parameter of interest, and let y be the available data. Then,
applying Bayes’ rule, we get
p(θ|y) = p(y|θ)p(θ)/p(y) (5)
Each element of the above expression has a specific name and interpretation:
p(θ) - is called the prior (probability) distribution of θ. It encapsulates
the knowledge available about θ, prior to observing the data y. As men-
tioned before, this knowledge is considered to be subjective.
p(y|θ) - is called the likelihood function. It is the link between the ob-
served data y and the model parameter θ. It encapsulates the information
which is contained in the observed data. The likelihood function p(y|θ) is
seen as a function of θ, while the observed data y is considered fixed. [27]
The likelihood function is not a probability distribution, as the values the
parameter θ can take are not restricted, hence if we integrate over θ (or sum
up over, in case of discrete θ), the obtained value would not necessarily in-
tegrate (or sum up) to 1, violating one of the requirements for a function to
be a probability distribution. [27]
p(θ|y) - is called the posterior (probability) distribution. It represents the
updated knowledge about the parameter θ after the data y has been ob-
served. It is one of the most important elements of Bayesian inference.
p(y) - is known as the evidence or the marginal likelihood, where
p(y) =
∫
p(θ)p(y|θ)dθ (6)
or, in case of θ-discrete:
p(y) =
∑
p(θ)p(y|θ). (7)
Since p(y) does not depend on θ, and the observed data y considered fixed,
p(y) is considered constant. [20] It serves as a normalizing constant for the
posterior distribution, ensuring that it would integrate (sum up) to 1, which
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is one of the requirements for a proper probability distribution. [27] p(y) is
often omitted, thus resulting in the unnormalized posterior distribution:
p(θ|y) ∝ p(θ)p(y|θ) (8)
Having explained how the prior and posterior work for a single-parameter
model, let us now briefly discuss how they would work in the case of multiple
parameters. For the purpose of demonstration, let us assume, without loss
of generality, that θ = (θ1, θ2), where each of θ1 and θ2 can be a vector. In
the case of multiple model parameters, the Bayes’ rule still holds, but in this
case we have a joint posterior density for θ1, θ2:
p(θ1, θ2|y) ∝ p(θ1, θ2)p(y|θ1, θ2). (9)
Let us now assume that we are only interested in the marginal posterior
distribution of θ1, p(θ1|y). In order to derive this, we simply average over θ2:
p(θ1|y) =
∫
p(θ1, θ2|y)dθ2 =
∫
p(θ1|θ2,y)p(θ2|y)dθ2[20] (10)
The integral above is rarely explicitly evaluated, however it is used to develop
a strategy for obtaining the posterior distributions of parameters. These
posteriors can be obtained by using marginal and conditional simulation.
This is, first θ2 is drawn from its marginal posterior distribution and then θ1
is drawn from its conditional distribution, given θ2. In this way the integral
above is evaluated indirectly. [20]
Having discussed the main points on prior and posterior distributions
of parameters, it is now worth looking into how parameter estimates are
obtained.
4.2.1.4 Parameter estimation
As mentioned earlier, in both frequentist and Bayesian inference, parameters
are considered fixed. However, the ways in which parameter estimates are
obtained is very different. Again, we are going to first provide the frequentist
method of parameter estimation, and then provide the Bayesian approach.
Maximum Likelihood Estimation
In frequentist inference, the most widely-used approach for estimating model
parameters is the Maximum Likelihood Estimation (MLE).[27]
In MLE, the estimated value of a parameter is obtained so that it maximizes
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the likelihood of observing the given data y under the considered model:
θˆMLE = arg max
θˆ
p(y|θ) (11)
The result of MLE is a point estimate of the parameter.
Bayesian Approaches to Parameter Estimation
As already mentioned, the emphasis in Bayesian inference is on finding the
posterior probability distribution for parameters, hence, naturally, when one
is seeking to obtain an estimate for a parameter, this is done through the
posterior distribution.
Bayesian parameter estimation approaches, also known as Bayesian esti-
mators, are defined through a minimization problem:
θˆ = arg min
θˆ
∫ ∫
C(θ − θˆ)p(x, θ)dxdθ (12)
where θˆ minimizes the average cost. [38]
The chosen cost function C(θ) is what determines the approach to parame-
ter estimation. There are several different approaches, but in this paper we
discuss in detail only the one used by the R package we used for creating our
LDL-aggregation model.
Minimum Mean Square Estimator (The Posterior Mean Approach)
As already mentioned, the parameter estimation approaches in Bayesian in-
ference are defined by the choice of the cost function C(θ). The Minimum
Mean Square Estimator is based on the cost function chosen, namely:
C(θ) = θ2 (13)
Thus, the minimization problem to be solved is then
θˆ = arg min
θˆ
∫ ∫
(θ − θˆ)2p(x, θ)dxdθ (14)
with a solution
θˆMMSE =
∫ ∫
θp(x, θ)dθ = E(θ|x). (15)
This is the mean of the posterior distribution, which minimizes the average
squared error, hence the name Minimum Mean Square Estimator (MMSE).[38]
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The R software package we use for model fitting, brms, uses MMSE to obtain
estimates for the model parameters.
Other commonly used estimators are the Maximum A Priori estimator and
the Median estimator, which are not discussed further, as they are beyond
the scope of this thesis.
Having discussed parameter estimation in Bayesian inference, it is worth
discussing how predictions of new values are made in the context of Bayesian
inference.
4.2.1.5 Posterior Predictive Distribution
Using the standard notation, let y be the observed values in an experiment.
Let p(θ) be the prior distribution of the parameters.
As already established, the emphasis in Bayesian inference is on finding out
the distributions of quantities of interest, rather than simply obtaining point
estimates. Thus, if one is interested in predicting a new observation y˜, one
can find its distribution, called the posterior predictive distribution, defined
as:
p(y˜|y) =
∫
p(y˜, θ|y)dθ
=
∫
p(y˜|θ,y)p(θ|y)dθ
=
∫
p(y˜|θ)p(θ|y)dθ
(16)
As one can see, the second and third row of the equation express the posterior
predictive as an average of conditional predictions over the posterior for θ.
Note also that the last row follows from the conditional independence of y
and y˜ given θ.[20]
Having discussed the necessary basics of Bayesian statistics, before we
delve into finding a suitable model for LDL aggregation, it is important to
quickly discuss the general form of regression models. This is important, as it
would prove useful later on when we have to take some modelling decisions.
4.2.2 General Form of a Regression Model
In regression modelling the focus falls on the relationship between a response
variable y and a set of predictors X, with a function f(X) modelling the
relationship, i.e
y = f(X) (17)
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In reality, however, the response variable y cannot be modelled exactly by
f(X), as it exhibits a certain level of randomness, i.e y is a random variable.
Hence, the regression model of a relationship between y and X is split into
two parts:
E[y|X] = f(X) (18)
y ∼ Dist(E[y|X]) (19)
Where the first expression is the deterministic part, with the function
f(X) being a deterministic function, modelling exactly the expected value of
the response variable y, conditioned on the set of predictors X. The second
expression is the stochastic part of the model, which handles the randomness
of y. The response variable y is allowed to vary around its mean, with
Dist being an arbitrary distribution which models that variation. [27] It is
worth pointing out that when we talk about a ”distribution” of the response
variable y in this context, we actually mean a distribution family. This is,
each observation yi of y is such that
yi ∼ Dist(E(yi|Xi)) (20)
The type of the distribution for each yi is Dist. From now on in this text
the terms ”response distribution” and ”distribution family of the response”
will be used interchangeably.
In summary, choosing a regression model to describe the relationship
between a response variable y and a set of predictors X means choosing a
function f(X) and a distribution for y. [27]
Having described the specifics around choosing a regression model, now it
is worth focusing on how the distribution of the response variable is chosen.
The choice of a response distribution is, to a large extent, based on the nature
of the data. In our case we have a continuous response variable, which
contains values of measurements of LDL radius that are strictly positive.
Hence, we need to look into distributions which incorporate this requirement.
4.2.2.1 Choosing the Distribution Family of the Response
The two distribution families which are most often used in the case of a
continuous response variable with strictly positive values, are the log-normal
and the gamma distribution families, hence in this thesis we only focus on
these two.
Lognormal Distribution
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The lognormal distribution is a continuous probability distribution. A con-
tinuous random variable X has a lognormal distribution LN(µx,σx) with µx -
mean and σx - standard deviation, if its logarithm Y = ln(X) Is such that Y ∼
N(µy, σy). [28] The probability density function of the lognormal distribution
LN(µx, σx) is given by
fX(x) =
1
σY
√
2pi
e
− 1
2
(
ln(x)−µY
σ2
Y
)2
, 0 < x <∞ (21)
where fX(x) is the probability density function of X, and
σY =
√√√√ln((σX
µX
)2
+ 1
)
(22)
and
µY = ln(µX)−
1
2
σ2y. (23)
[10] As one can see, the lognormal distribution is only defined for strictly
non-negative values, which is what is required in our case.
Gamma Distribution
The gamma distribution is a continuous probability distribution. A con-
tinuous random variable X has a gamma distribution with a shape a and a
rate parameter b if:
p(x) =

ba
Γ(a)
xa−1e−bx, x > 0
0, otherwise
with mean and variance, respectively
E[X] =
a
b
, σ2X =
a
b2
. [39]
which means that the variance of a variable yi with a Gamma distribution
can be expressed as a function of its mean:
V ar(yi) =
1
b
µi (24)
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which means that the variance for higher values yi of the response variable y
will be higher, which is what we need in our case, as the uncertainty of the
measurements of LDL radius increases as the values of these measurements
grow bigger.
In addition, the Gamma distribution is only defined for strictly non-
negative values, which is what we need in our case where the response variable
contains values of LDL radius, which are all strictly positive.
Having discussed appropriate distribution families for the response dis-
tribution, now it is worth discussing a concept, which is closely related to
selecting a distribution family - the link function.
4.2.2.2 Link Function
The easiest way to introduce the link function is to discuss it in the con-
text of Generalized Linear Models (GLM), hence, we first start with a brief
discussion of GLM.
Generalized Linear Models can be seen as an extension to ordinary linear
regression, as they allow for flexibility in the choice of response variable dis-
tribution. In addition to normal distribution, under GLM a response variable
can have a non-normal distribution, such as Gamma, Poisson, etc. [5] In the
original formulation of GLM by Nelder and Wedderburn, the distribution
of the response variable is a member of the exponential family, however in
subsequent works extended GLMs to some non-exponential families. [26]
A GLM has three components:
• The distribution family of the response variable y.For simplification of the
following explanations, let us consider a single observation of the response
variable - yi.
• A linear predictor ηi = β0 + β1f1(xi1) + β2f2(xi2) + · · · + βkfk(xik) where
β0, β1, .., βk are unknown parameters and f1(.), f2(.), ..., fk(.) are prespecified
functions of the explanatory variables, which can be nonlinear.
• A link function g(.) is a smooth and invertible function which transforms
the mean µ = E(Y |X) to the linear predictor:
g(µ) = β0 + β1f1(xi1) + β2f2(xi2) + · · ·+ βkfk(xik). (25)
[26]
Since the link function is invertible, one can also write
µ = g−1(η) (26)
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[26] The inverse of the link function is often called mean function.
Apart from mapping E(y|X) to a linear predictor, the link function can
be useful in other ways. For example, it could be used to remove restrictions
on the range of the expected response µ. [26] For example, let y be a response
variable representing count data. Then it can only take non-negative integer
values i.e 0,1,2, . . . Let yi be an observation. Then, the expected count µi
would also be non-negative (although not necessarily an integer). A log-
link function would then map µi to the whole real line, thus allowing the
parameters that need to be estimated to take any value.
Having discussed the distribution families which we are going to exper-
iment with for our response variable, we now proceed to discuss the next
piece of theory which we will later on be applying to model LDL aggregation
- nonlinear mixed-effects models.
4.2.3 Nonlinear Mixed-Effects Model
A nonlinear mixed-effects model is a nonlinear model which contains both
fixed and random effects. Fixed and random effects can be defined in several
ways, some of which are outlined in [19]. The definition we use in this thesis
is the following:
• Fixed effects are model parameters which are constant across all individu-
als in a population. [19]
• Random effects are model parameters which are allowed to vary across
individuals or groups of individuals. [19]
In literature these two terms have been referred to with different names.
Fixed effects are also known as population effects and constant effects. Ran-
dom effects are also known as varying effects. In this thesis, however, we are
going to stick to the terms ”fixed effects” and ”random effects”, as these are
the most commonly used ones.
The goal of a mixed-effects model is to predict a response y through
a linear combination η of predictors, transformed by the inverse link g−1,
assuming a specific distribution Dist for the response y. For an observation
yi of the response y, we write
yi ∼ Dist(g−1(ηi), θ) (27)
The parameter θ describes any additional parameters specific for the dis-
tribution family that typically do not vary across observations, e.g standard
CHAPTER 4. METHODS 39
deviation sigma of a normal distribution, or the shape parameter alpha of a
Gamma distribution. [9]
The linear predictor can be written as
η = Xβ + Zu (28)
Where beta are the fixed effects, u are the random effects, and X and Z are
the fixed- and random-effect design matrices. The response y as well as X
and Z make up the data, while β, u, and θ are the model parameters that
need to be estimated. [9]
As mentioned earlier, the random effects are supposed to vary either
across single individuals, or between groups of individuals, defined by group-
ing factors. For example, one could study the variance of GPA across schools.
In this case one can consider school as a grouping factor, and each individual
school can be thought of as a group level of this factor.
Let u be the group-level parameters. Then it is assumed that
u ∼ N(0,Σ) (29)
[9]
As it is in general the case, the covariances between group-level parame-
ters of different grouping factors are assumed to be zero. Thus, Z and u can
be split up into several matrices Zk and vectors uk, where k is the grouping
factor index, simplifying the model to
uk ∼ N(0,Σk) (30)
[9] In addition, even though not always, group-level parameters associated
with different levels, (with index j) of the same grouping factor are usually
also assumed to be independent, resulting in
ukj ∼ N(0,Σkj) (31)
It is worth noting that in this case we talk about η as a linear predictor, as
this is an easier and more conventional way to explain mixed-effects models.
However, it is also possible for η to contain parameters which are nonlinear,
which can still be easily handled by software packages used for fitting the
mixed-effects model.
Now that we have explained the essence of mixed-effects models, we pro-
ceed to the mathematical formulation of LDL aggregation, which is at the
focus of this thesis.
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4.2.4 Mathematical Model for LDL Aggregation
The mathematical model chosen to describe LDL aggregation is the model
used in the original paper. [35] The model is a slightly modified general-
ized logistic function, also known as Richard’s curve. The general form of
Richard’s curve was first developed by Richard’s [34] with the aim of mod-
elling time-dependent growth. It is commonly used in various branches of
biology, hence making it a natural choice for modelling of this biological pro-
cess. Before we proceed to discussing the elements of the LDL aggregation
model, it is worth taking a look at how our data ”behaves”, in order to give
the reader some context. The figure below shows LDL aggregation in time
for one of the samples in our dataset.
Figure 4.1: LDL aggregation measured in time
As one can see, the data points, representing the size of LDL particles at
certain time points, form an S-shape. At the beginning, the aggregation of
LDL particles appears to be slower, judging by the size of the aggregates up
until around 2h. Then as one can see, the size of the aggregates increases
rapidly, forming a steep slope, until it slows down again and reaches a plateau.
This behaviour of the LDL data is modelled as:
yit = β +
α− β
1 + exp(γ−t
δ
)
(32)
where
• β - the bottom asymptote, obtained when t → −∞, which represents
the original size of the LDL particles
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• α - the top asymptote, obtained when t → +∞,which represents the the-
oretical maximum size of LDL aggregates
• γ - the point of inflection, i.e. the time point where the curve transi-
tions from concave upwards to concave downwards. By definition, this is the
point of the curve with the steepest upward slope
• δ - the slope at the inflection point gamma
• t - is the explanatory variable which is continuous and represents time.
[35]
The model provided above, however, could only be used to estimate the
average of the response in different time points, based on the measurements
for all patients. However, our goal is to fit a separate model to the data
corresponding to each sample, i.e data of a patient in one of the two conditions
- before or after the operation. In order to allow for the parameters to vary
according to each subset of the data that we fit a model to, we have to use a
nonlinear mixed-effects model. The strategy is to calculate fixed effects for
the parameters, which would result in a model which gives the average of the
response, and then calculate the random effects for some of the parameters,
which would result in more flexible models that describe more accurately the
behaviour of each subset of data that we fit a model to.
However, the model we introduced in Eq.(32) has four parameters to be
estimated, which makes it quite complex. Calculating a fixed and a random
effect which correspond to each of these four parameters would make it even
more complex. We only have 368 data points, split between 56 subsets, with
each subset representing the LDL aggregation data of a certain patient in
one of the two conditions - before or after the operation. Our goal is to fit
a separate model for each of these 56 subsets, which means fitting a model
with four fixed and four random effects based, on average, on less than 7
data points. This means that we need to find ways to simplify the model.
As a result, the following modelling decisions were made:
• Set parameter beta to a constant: As mentioned earlier, beta is the
lower asymptote of the model, which sets a lower limit for the size of LDL
particles. After inspecting the lowest value for each of the 56 subsets, we
established that none of them goes lower than 15nm, hence, we decided to
set beta = 15, and thus simplify the model. And even though for some of the
subsets the lowest value was slightly more than 15, setting a common lower
limit was a reasonable compromise to make, as the beta-term is just a linear
CHAPTER 4. METHODS 42
term and hence does not have such a strong influence on the model.
• Use only a fixed effect for delta: In order to simplify the model fur-
ther, we decided to only use a fixed effect for the slope delta. This decision
was made after trying to fit a model with both fixed and random effects for
alpha, gamma and delta, which resulted in a model which was too complex
and whose parameters could not be estimated.
• Use both fixed and random effects for alpha and gamma: We
decided to use both fixed and random effects for each of alpha and gamma.
The reason for this is because after inspecting the subsets, we established
that the highest values for the subsets varied, hence, only selecting a fixed
effect for alpha would not have been enough, hence we added a random effect
to let the upper asymptote vary across samples. In addition, after a visual
inspection of the plots for the separate subsets, we established that the time
point where the steep part of each of the plots start also varies, hence, in
addition to a fixed effect for gamma, we had to add a random effect to allow
the inflection vary across subsets.
It is worth pointing out that here we talk about including random effects
for some of the parameters, but we do not make clear what the nature of
these random effects is - do they vary across the 56 separate samples (subsets
of data points), or per individual, etc. This is in fact an important question
which we discuss in detail in the Model Fitting subsection later on. Before
continuing to implementing the models, however, we first discuss the model
comparison criteria which we use later on to evaluate the developed models.
4.2.5 Model Checking and Comparison Criteria
A thorough model-fitting process would usually involve developing several
different models to fit to the same data. Once the models are fit, one needs
to perform model checking, in order to ensure that the predictions generated
by the models are reasonable.
4.2.5.1 Model Checking
One way to conduct model checking is through posterior predictive checking
(PPC). It involves comparing the observed data y to replicated data gener-
ated under the model, usually denoted by yrep. If the model is good, then
the data replicated under the model should be very similar to the observed
data. [20] Now, let us elaborate on what yrep is and how it is generated.
yrep refers to replicating the experiment which generated y, with the same
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values for the explanatory variables X, and obtaining as many values as the
number of observations in y. The distribution of the replicated data yrep is
defined as:
p(yrep|y) =
∫
p(yrep|θ)p(y|θ)dθ (33)
Note that in this case we actually condition on the predictors X as well, but
it has been omitted for simplicity. Since this integral is usually difficult to
evaluate, the posterior predictive distribution can be computed through sim-
ulation:
1. Take N draws θ1, . . . , θN from the posterior distribution p(θ|y).
2. For each draw θs, s=1,...,N, an entire vector of simulated values yreps is,
drawn from the posterior predictive distribution, simulating from the model
conditional on the parameters θS. [17]
There are several ways to conduct posterior predictive checking. One way is
through visualization. For example, generating a plot which contains the
distribution of y and the distributions of some of the simulated datasets yrep.
An example is given in the figure below.
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Figure 4.2: Distributions of observations and simulated datasets
Here the thick dark-blue line represents the distribution of the observed
data, whereas the thin light-blue lines represent the distributions of the sim-
ulated data, calculated for the same values of the explanatory variables as
the original data. As one can see, the distributions displayed are reasonably
similar, suggesting that the fitted model is reasonable.
In addition, PPC can be done through calculation of test quantities. A
test quantity T(y,θ), also known as discrepancy measure, is a scalar summary
of the parameters and the data. It is a standard way to compare observed
data y to repeated simulations yrep. The role of test quantities in Bayesian
model checking is very similar to the role of test statistics in frequentist
testing. When a test quantity is only dependent on the data, it is called
test statistic and is denoted by T(y). In Bayesian context, test statistics can
be generalized to allow for their dependence on the model parameters under
the posterior distribution. This is a useful way to summarize discrepancies
between a given model and the observed data. [20] In practice this is done
by calculating the test statistic T(yrep) for each simulated set of values yrep,
and the distribution of these test statistics is generated. Once this is done,
this distribution is then compared to the test statistic T(y), calculated from
the observed data y. Related to these test statistics, one can compute the
posterior predictive p-value, defined as
p = Pr(T (yrep, θ) ≥ T (y, θ)|y)
=
∫
IT (yrep,θ)≥T (y,θ)p(yrep|θ)p(θ|y)dyrepdθ,
(34)
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where I is an indicator function.
What the posterior predictive p-value evaluates is how likely it is for the
test statistic value T(yrep) for data generated from the model to be more
extreme than the test statistic T(y). In practice what this means is that an
indicator of a good model would be a p-value, which is close to 0.5, while
anything too close to 0 or 1 would indicate potential problems with the
model. Since this integral is often difficult to evaluate in practice, this can
be done through simulation, as described above. First we would draw values
for the parameters from the posterior distribution and would then use these
to simulate sets of observations yrep. We would then calculate the proportion
of cases in which T( yrep) > T( y). One can also generate a plot of the result,
using R:
Figure 4.3: Test quantity T(yrep) for the mean, compared to mean of the
observations, T(y)
The light-blue histogram is the distribution of T(yrep) values calculated,
in this case the mean. The dark line represents the value of T( y). If a model
is good, then we would expect the mean of this distribution to be as close as
possible to the dark line, which is the case in this situation.
Having discussed in detail posterior predictive checking, now we proceed
to discussing one of the methods for comparing Bayesian models.
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4.2.5.2 Model Comparison
There are several different ways to compare models, based on their predic-
tive accuracy. However in this thesis we will only focus on one of them -
Leave-One-Out Cross-Validation (LOO-CV, or just LOO), which we later on
use to compare the models we developed.
Leave-One-Out Cross-Validation
Leave-one-out Cross-Validation is a method used for estimating the pointwise
out-of-sample prediction accuracy of a fitted Bayesian model. LOO is based
on evaluating the log-likelihood at values of the parameters drawn from the
posterior distribution. [40]
However, if one wants to conduct LOO in practice, this would mean refit-
ting a model N times (where N is the number of data points in a data set),
retaining one of the data points for testing each time, and then evaluating
how well the model does predicting it. This makes conducting exact LOO
very computationally expensive. Hence alternative ways for evaluating LOO
have been developed.
One of the most commonly used ways for approximating LOO is the
Pareto-Smooth Importance Sampling (PSIS). PSIS calculates LOO using im-
portance weights, and then fits a Pareto distribution to the upper-tail of the
distribution of these importance weights. We are now going to discuss how
this procedure works. It is important to note that this is only meant as an
overview, so if the reader is interested in the full picture, they should refer
to the original paper [40].
The Bayesian leave-one-out estimate of the out-of-sample predictive fit is
given by the expected log-predictive density, defined as:
elpdloo =
n∑
i=1
log(p(yi|y−i))dθ, (35)
where
p(yi|y−i) =
∫
p(yi|θ)p(θ|y−i)dθ (36)
is the LOO predictive density given the data without the point yi. [40] Pro-
vided that the data points are conditionally independent in the data model,
one can evaluate the predictive density (36) using values for the parameters
θs, s=1,...,S, which are drawn from the posterior p(θ|y), using importance
ratios :
rsi =
1
p(yi|θs) ∝
p(θs|y−i)
p(θs|y) (37)
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[40]
These are then used for the Pareto-Smooth Importance Sampling approx-
imation of LOO, which is done in the following way:
1. A generalized Pareto distribution is fit to the 20% largest importance
rations rs, computed above. The importance ratios are computed separately
for each held-out point yi. It is worth noting that the Pareto distribution fit
is not sensitive to the cutoff proportion. When the number of draws from
the posterior grows very large, the cutoff value should be made smaller. [40]
2. The importance ratios used to fit the generalized Pareto distribution
are then stabilized by replacing them with the expected values of the order
statistics of the fitted distribution F−1
(
z−1/2
M
)
where z= 1,..., M, and M is
the number of importance ratios used to fit the generalized Pareto distribu-
tion (M = 0.2S), and F−1 is the inverse-CDF of the fitted distribution. These
new weights are then labeled as w˜si , where s is the index of the simulation
draw and i is the index of the data point. Thus, for each data point yi there
is a vector of S weights, w˜i. [40]
3. In order to guarantee the finite variance of the LOO estimate, each of
the vectors w˜i is truncated at S
3/4w¯i , where w¯i is the average of the weights
in w˜i. In this case truncating means that, for a weight w
s
i , we would get w
s
i
= min(rsi , S
3/4w¯i). The truncated weights are then relabeled as w
s
i . [40]
The listed steps are performed for each point. So, for each point yi we have a
corresponding vector wi, containing S weights. These weights are in general
considered to be more stable, compared to the importance ratio which were
used to calculate them. [40]
These weights are then used to obtain the LOO estimates. The PSIS estimate
of the LOO expected log pointwise predictive density is defined as:
ˆelpdpsis−loo =
n∑
i=1
log
(∑S
s=1w
s
i p(yi|θs)∑S
s=1w
s
i
)
(38)
[40] The reliability of this estimate can be evaluated using shape parameters
kˆ of the generalized Pareto distributions, which are fit for the raw importance
ratios rsi , for each data point yi:
• If for all Pareto distributions fit k < 0.5 , the variance of the raw im-
portance ratios rs is finite, the Central Limit Theorem (CLT) holds and the
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LOO estimate converges fast. [40]
• For k in [1
2
, 1], the variance of the ratios rs is infinite but the mean ex-
ists, the generalized CLT for stable distributions holds. In this case the
convergence of the estimate is slower. And while the variance of the PSIS-
LOO estimate is finite, it is likely to be large. [40]
• For k > 1, none of the variance or mean of the raw ratios distribution
exist. And, again, while it is finite, the variance of the PSIS estimate is
likely to be large. [40]
In practice, observations with k ≤ 0.7 are still considered reasonable. How-
ever, if for a point yi k > 0.7, the estimate of the LOO predictive density
given the data without the point yi (36) cannot be accurately calculated,
hence it is recommended that the model is refitted without the point yi and
the LOO predictive density for the problematic point is calculated directly.
The points with k > 0.7 are called influential points, meaning that they influ-
ence the posterior distribution more strongly than the rest of the data points.
Having a model with several influential points is quite common, however, if
a model has a very large number of influential points, this is usually a sign
of a problem with the model.
Comparing models using PSIS-LOO simply means comparing their expected
log pointwise predictive density (ELPD). In the case of only two models, as
it is the case in this thesis, the model with the bigger ELPD is the one which
should be chosen.
Having discussed the basics of Bayesian theory which are used in this
thesis, now we move on to discuss the methods which we use to evaluate
correlations between our variables of interest, as well as the statistical tests
used to investigate change in variables between the before- and after-states.
4.2.6 Methods for Testing Change in Paired Variables
As mentioned earlier, one of the main points of this thesis is to evaluate
whether there is a significant change in the variables of interest. This change
can be tested in two different ways.
4.2.6.1 Paired t-test
The paired t-test is a standard statistical procedure used to calculate the
mean difference between two correlated or dependent sets of observations.
[13] In our case we have two sets of measurements of the same variable -
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values of LDL aggregation, percentage of a specific surface or core lipid, clin-
ical measurements, taken from a set of individuals before and after bariatric
surgery. The fact that these measurements were taken repeatedly - before
and after the operation - from the same set of individuals makes the two sets
dependent. It is important to point out that both vectors of measurements
have the same length and the values contained in the same position of the
vectors correspond to the before- and after-measurement of the variable of
interest of the same individual, i.e. these are paired observations.
Null Hypothesis: The null hypothesis of the paired t-test is that the mean
difference between the aforementioned paired observations is 0.
Assumptions: First, it is important to point out that the paired t-test
is used when the two sets contain values of a continuous variable. The use
of the paired t-test is based on the assumption that the differences between
paired observations are normally distributed. [29] The normality assumption
is quite loose, as the test is fairly robust. In cases of extreme non-normality,
however, the Wilcoxon signed-rank test is used. [29]
Meaning of p-value: In order to explain how the paired t-test work, let us
first briefly explain how it works. Let the number of pairs of observations be
n. The difference for each pair of observations is calculated. The mean x¯ of
these is then calculated. The standard deviation s of the differences is then
calculated. These are then used to calculate the test statistic ts:
ts = x¯/(s/
√
(n)) (39)
[29] The test statistic grows bigger as the mean x¯ grows bigger, the standard
deviation grows smaller, or as the sample size grows. Then one calculates
the probability of obtaining this value of ts under a true null hypothesis,
using the t-distribution - the p-value for the paired t-test. The shape of the
t-distribution and thus the probability of obtaining ts are determined by the
degrees of freedom. In this case the number of degrees of freedom is n-1. [29]
Applying a paired t-test is, in practice, applying a one-sample t-test to the
set of differences between the paired observations. [29]
In case the distribution of the differences between the paired observations
is severely non-normal, the Wilcoxon signed-rank test is used.
4.2.6.2 Wilcoxon signed-rank test
Wilcoxon signed-rank test is also used to compare two dependent sets of data,
as described in the section about paired t-test above. It is used instead of a
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paired t-test when the distribution of the differences of paired observations
is heavily non-normal. [29]
Null Hypothesis: The null hypothesis for the Wilcoxon signed-rank test
is that the median of the differences of paired observations is 0. It is worth
pointing out that it differs from the null hypothesis of the paired t-test, where
the mean of the differences was compared to 0.
For the sake of brevity, we omit the explanation of how the test statistic W
for the Wilcoxon signed-rank test is calculated, as the steps taken are trivial
and readily available in introductory applied statistics literature. [29]
Meaning of p-value: Provided that the data were sampled from a popu-
lation with a median equal to 0, how likely is it to randomly select N points
and obtain a value for the median which is as far or further from 0 as the
one obtained from the given set of differences. [24]
4.2.7 Method for Evaluating Correlation
In this thesis we evaluate the correlation between variables of interest using
Spearman’s rank correlaiton.
4.2.7.1 Spearman’s rank correlation
Spearman’s rank correlation was chosen as it does not assume that any of
the two variables whose correlation is studied are normally distributed or
homoscedastic. [29], thus making it less restrictive, compared to the more
commonly used Pearson’s correlation which assumes normality. In addition,
Spearman’s correlation does not assume that the relationship between the
variables of interest is linear; one can use Spearman’s correlation as long as
the relationship between the two variables is monotonic [29], thus making it
less restrictive and more suitable for the nature of our data.
Null Hypothesis: The null hypothesis for the Spearman’s rank correla-
tion is that the correlation coefficient rho is equal to 0, which would mean
that there is no association between the variables at hand. [29]
4.2.8 Multiple Comparisons Adjustment
When a large number of statistical tests are conducted at the same time in a
study, there arises the possibility of obtaining statistically significant results
for some of them, i.e. p-value < 0.05, purely by chance. This problem of
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conducting multiple statistical tests at the same time, and as a result rejecting
a true null hypothesis due to chance, is known as the multiple comparisons
problem. Rejecting a true null hypothesis is also known as Type 1 Error
or a false positive. The multiple comparisons problem has been a subject
of interest in recent years, due to its importance for all scientific disciplines.
[29] Several approaches to controlling for false positives have been developed.
Two of the more prominent ones are controlling for Familywise Error Rate
(FWER), and finding an acceptable False Discovery Rate (FDR).
Familywise Error Rate is the probability of the set of rejected null
hypotheses in an experiment containing at least one falsely rejected null hy-
pothesis. [23] What FWER adjustment methods do is set a level α, denoting
the probability of rejecting at least one true null hypothesis, and based on
that they impose some adjustments to the set of p-values obtained from the
conducted hypothesis tests. Based on the adjustments made for the p-values,
usually only a subset of the hypothesis tests which originally yielded statisti-
cally significant results are then regarded as significant, corrected for multiple
comparisons.
FWER methods are sometimes criticized as being too conservative [23], in
the sense that, after the FWER adjustment has been applied, very few results
rejecting null hypotheses are considered significant. This could be a problem,
as it might result in actually omitting some important scientific result which
was rendered insignificant by the multiple comparisons adjustment.
In contrast, False Discovery Rate assesses the expected proportion of
falsely rejected null hypotheses (false discoveries) in the whole set of rejected
null hypotheses. [23] Similarly to FWER methods, a false discovery rate
α is chosen, depending on the nature of the problem, which represents the
proportion of false discoveries, which are expected to be made. If a follow-up
study of a rejected null hypothesis is expensive or can have a huge impact, i.e.
implementing a new medical treatment, then, naturally, the false discovery
rate is set really low. And, conversely, if a follow-up study is not expensive,
one can select a higher α, sometimes as high as 0.2. Most methods developed
to control for FWER and FDR assume that the multiple statistical tests
conducted are independent of each other. [29] [23] However, in our case,
some of the variables about which we form and test hypotheses, have some
type of dependency. Under these circumstances, the Benjamini-Yekutieli
False Discovery Rate Adjustment is used.
4.2.8.1 Benjamini-Yekutieli False Discovery Rate Adjustment
In our case, some of the variables in our datasets exhibit some type of depen-
dency between each other. For example, we have a dataset of clinical data
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which contains the variables weight and Body Mass Index (BMI). The body
mass index is defined as BMI = weight/height2, which means that these
two variables are correlated. Furthermore, if we conduct hypothesis testing,
for example, about the change in weight and BMI before and after bariatric
surgery, the test statistics we use would also be dependent. Hence, in this
case we require a method which controls for multiple testing and takes into
account the dependence of the tests, and as a result the dependence of their
respective p-values.
The test we chose, which fulfils these requirements is called the Benjamini-
Yekutieli test. It controls the FDR and is valid under a general dependence
of the p-values. [23] Similar to other FDR procedures, Benjamini-Yekutieli
imposes an adjustment for the p-values, which usually results in only a sub-
set of the rejecting null hypotheses is considered significant. For the sake
of brevity, we are not going to explore further how and why the Benjamini-
Yekutieli adjustment works. If the reader is interested, they are advised to
refer to the original paper. [6]
Another question which arises when multiple comparisons adjustment is to
be done, is the question of grouping the hypotheses in meaningful categories,
also known as families. The reason for that is because multiple comparisons
adjustments are usually in some way dependent on the number of hypotheses
tested. Testing of very large number of hypotheses together usually results
in very strict adjustment which dramatically reduces the number of rejected
null hypotheses which are considered significant. One common way of dealing
with this problem is to split the set of hypotheses to be tested into groups,
based on some underlying similarity. A rule of thumb is to group together the
hypotheses which might lead to a single publication. [23] In this way, if one
group of researchers conduct an experiment, which generates 100 hypotheses
to be tested, and another group conduct a smaller experiment, which only
focuses on a testing a subset of these hypotheses, then having some kind of
grouping, based on similarity between these hypotheses, allows for a certain
level of consistency between the final results. However, this convention is
still to some extent arbitrary and does not fully solve the problem.
Now that we have discussed the statistical tests used for testing the hy-
potheses of interest, it is worth briefly discussing the package used for im-
plementing our LDL aggregation models. While we will try to abstain from
going too deep into the technical details, it is worth considering the way in
which the programming of the model is done, as it would allow us to put into
context the modelling decisions we make in the implementation part.
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4.3 Technical Aspects of Model Fitting
In this section we are going to briefly describe the technicalities about fitting
our models in R, as well as discuss some convergence diagnostics to ensure
that a model has been fit.
4.3.1 The brms Package
In order to implement our Bayesian models, we used R statistical language,
which is a standard in statistical modelling. And, more specifically, we used
the brms (Bayesian Regression Modelling using Stan) package. While brms
is an R package, it uses the probabilistic programming language Stan on
the back-end. Stan is a probabilistic programming language for perform-
ing full Bayesian inference. The brms package is an easy-to-use interface
for Stan, with excellent documentation and a huge support network in the
specialized forum [36], which, from a practical point of view, was another
reason to choose the Bayesian approach for this thesis. The brms package
uses the No-U-Turn Sampler (NUTS) method, which is an extension of the
Hamiltonian Monte Carlo (HMC), a method for drawing random samples
from the posterior distribution of developed models. [9] HMC is, in its turn,
part of a larger class of algorithms, used for sampling from a distribution -
Markov Chain Monte Carlo (MCMC). Compared to other packages which
use Metropolitan-Hastings or Gibbs algorithms for sampling, brms has the
advantage because the NUTS and HMC algorithms converge much quicker
for more complicated models, regardless of whether the prior distributions
chosen are conjugate or not [9] which is another reason for choosing it.
Before we continue with fitting the models, we are now going to briefly
discuss a piece of code written in R, using the syntax for brms, which shows
the necessary code to fit a Bayesian nonlinear mixed-effects model.
listings
1 fit_model <- function(Data){
2
3 fit <- brm(
4
5
6 bf(
7 # (1) Declare the formula formula for the model
8 LDL ~ log(15 + (alpha -15) / (1 + exp ((gamma -Time) / delta))),
9
10 # (2) Declare parameters
11 alpha ~ 1 + (1| Pat/Cat),
12 gamma ~ 1 + (1| Pat/Cat),
13 delta ~ 1,
14 nl = TRUE),
15
16 # (3) Declare priors
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17
18 prior = c(
19
20 # (3.1) Declare priors for fixed effects
21
22 prior(normal (3000 , 2000) , class="b",lb=0, nlpar = "alpha"),
23 prior(normal (2.5 ,2), class="b",lb=0, nlpar = "gamma"),
24 prior(normal (0.2 ,1), class="b", lb=0, ub=1, nlpar = "delta"),
25
26 # (3.2) Declare priors for other distribution parameters
27 prior(gamma (0.01, 0.01) , class="shape"),
28
29 # (3.3) Declare priors for SD of random effects
30
31 prior(normal (0,2), class="sd", group="Pat:Cat", coef="Intercept",
nlpar="gamma"),
32 prior(normal (0 ,1000), class="sd",group="Pat:Cat", coef="Intercept",
nlpar="alpha")),
33
34 data = Data ,
35
36 #(4) Declare family distirbution for the response variable and link -
funcition
37 family = Gamma(link="log"),
38 chains = 4,
39 iter =50000 ,
40 warmup = 1000,
41 cores = getOption("mc.cores",1L),
42 thin = 1,
43 control = list(adapt_delta = 0.99999 , stepsize =0.00001 , max_treedepth
=15)
44 )
45
46 return(fit)
47 }
Let us now go through the main steps marked with comments in the code
above:
1. Step 1: This is where the model formula is declared.
LDL ∼ log(15 + (alpha-15) / (1 + exp ((gamma-Time))))
On the left-hand side we have the response variable, in our case LDL, and
on the right hand side we have the model formula. Note that in this case
we have the original formula for our LDL aggregation model, which is inside
a log() function. This is because in this example the chosen link function is
the log-link and we want
E(LDL|X)= 15 + (alpha-15) / (1 + exp ((gamma-Time) / delta))
= exp(log(15 + (alpha-15) / (1 + exp ((gamma-Time)),
where exp() is the inverse-link function.
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2. Step 2: In this step we declare the parameters as a combination of
fixed and random effects. In this case, for example, we have
alpha ∼ 1 + (1|Pat/Cat)
Which means that for the parameter alpha we have a fixed effect and
we also have 2 random effects - one which varies between patients (1|Pat),
and one effect which is within the group factor Pat (patient), which varies
between the two categories of Pat (B - before and A-after).
3. Step 3: This is where the priors are set.
3.1. Priors for the parameters
This is where the priors for the parameters are set. Here one can also set
upper and lower bounds which make sense for the parameters in the specific
context.
3.2. Priors for response distribution parameters
These are usually default, so the user does not need to worry about them.
3.3. Priors for the SD of random effects
As already mentioned, random effects are assumed to be normally distributed
with mean 0, so the prior is used to evaluate the standard deviation.
4. Step 4: This is where the family distribution and the link-function
are declared.
Now that we have discussed how a model is declared, we are going to briefly
talk about convergence diagnostics for the sampling algorithm, used to ap-
proximate the posterior distrobution.
4.3.2 Convergence Diagnostics
As mentioned earlier, the brms package uses the NUTS sampling algorithm,
which is used to draw samples from the posterior distribution. Briefly, the
way this sampler works is, it starts off from some initial value and, based
on a set of rules, makes further draws (iterations), with the idea that at
some point the draws it makes are actually from the posterior distribution.
When the algorithm gets to the point of drawing samples from the posterior
distribution, we talk about convergence to the posterior distribution. For the
sake of brevity, we are not going to elaborate further on how this works in
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theory, but one can easily look this up in the literature. Various diagnostics
have been devised to evaluate convergence.
To start with, a sampling algorithm is usually run on multiple different
chains. This is, it is ran in parallel for several different initial values. The
algorithm is considered to converge if eventually the values drawn from each
chain are quite similar.
The ”similarity” is measured by the value Rˆ, known as potential scale re-
duction factor. For each parameter of interest, the variance for each chain is
estimated (after discarding the initial M draws from each chain, as these are
considered to be far away from values in the posterior). Then the average of
these within-chain variances is calculated. Additionally, the variance of all
chains mixed together is calculated. The calculated Rˆ is the square root of
the mixed variance, divided by the average of the within-variances. When
convergence has been reached, all chains will have mixed, and thus the dis-
tribution of the draws between and within chains will be identical. Which
means that an Rˆ would be close to 1 (in practice values less than 1.1 are
considered to be indicating convergence). [21]
In addition, when evaluating the convergence to the posterior, another
factor to look at is the effective sample size(ESS). Ideally, samples drawn by
a sampling algorithm would be independent of each other. However, this is
usually not the case. The existing autocorrelation within chains increases the
uncertainty of the estimates. This increase of uncertainty can be measured
by using ESS. When independent samples are considered, the uncertainty of
estimates is bound to the number of samples N. When considering dependent
samples, N is replaced by the effective sample size Neff , which is defined as
the number of independent samples, which have the same estimation power
as the autocorrelated samples. [2] This means that the smaller Neff , the
greater the uncertainty about the obtained parameter estimates is. As a rule
of thumb, an Neff smaller than 10% of the number of total iterations run is
alarming and indicates that the chains of the sampling algorithm should be
run longer, in order to converge.
We now proceed to fitting the developed models, where we will be dis-
cussing the configurations chosen in the context of the 4-step plan discussed
above.
4.4 Model Fitting
In this section we are going to discuss two different nonlinear mixed-effects
models which were fit to model LDL aggregation, do model checking and
model comparison on these models.
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As noted earlier on, the parameter β was set to a constant, β = 15, in
order to simplify the model. In addition, it was decided that the parameter δ
would be a fixed effect. Hence, the possible variations of the model would, in
essence, be centered around experimenting with random effects for α and γ.
In addition, as mentioned earlier, the idea of mixed-effects models is to allow
more flexibility of the fitted models, with the values of the model parameters
varying across individuals and groups. In our case we have 56 subsets of
data, each of which containing LDL aggregation data for a specific patient
in one of the two conditions - before- or after-operation. For brevity, in the
next section we will refer to these subsets as samples
4.4.1 Model 1
4.4.1.1 Model Declaration
As stated above, we will describe this model based on the four steps sug-
gested above.
1. Model formula
The model formula for this model is the one stated in (32).
2. Fixed and random effects related to parameters
Using the notation of brms, the model parameters are defined as:
α ∼ 1 + Cat+ 1|Pat
γ ∼ 1 + Cat+ 1|Pat
δ ∼ 1.
In the case of α and γ we have two fixed effects and one group-level random
effect.
The first fixed effect is shared by all individuals. The second effect is related
to the variable Category, denoted by Cat. This variable has two levels - B-
before and A-after, corresponding to before- and after-operation states of the
patients. What this fixed effect does is it serves as a difference between the
before- and after-condition of each patient, and is constant across patients.
An estimate of this fixed parameter is obtained for only one of the levels of
the variable - in our case CatB. In our case estimates αCATB and γCATB are
obtained, and these are then added to, respectively, the α- and γ-values only
of samples, representing a patient in a before-operation state. Note that the
value of αCATB and γCATB is the same for all individuals in before-operation
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state. Note that the idea of this fixed effect is actually consistent with the
idea of a non-zero, i.e. significant average difference between before- and
after-operation values of LDL.
The group-level random effect 1|Pat varies across patients. This means
that the models for the samples, related to the same patient, would have the
same value value for the random effect 1|Pat.
3. Priors
3.1. Priors for fixed effects
As already mentioned, all three model parameters have a fixed effect associ-
ated with them. The priors we chose for these fixed effects are, respectively:
αfixed ∼ N(3000, 2000)
The reason why this distribution was chosen is because we do not have much
information about this parameter, and a normal distribution is typically used
in this case. Such distribution, which does not provide a lot of insight into a
parameter, but still incorporates some level of knowledge, is usually referred
to as weakly informative. Based on previous experiments and advice from
a domain expert, we know that usually this type of LDL aggregation data
grows and settles at a plateau which is somewhere around 3000, hence the
mean we chose is 3000. As one can see, however, the standard deviation is
set very high, to capture the high level of uncertainty around α.
In addition, we have the fixed effect for α, related to Category, αCatB.
αCatB ∼ N(0, 1000)
Since we have no information about the distribution of this effect, we choose
a normal distribution with mean 0 and a large standard deviation, 1000, to
capture the large level of uncertainty around this αCatB.
For the fixed effect for gamma, γfixed, we have
γfixed ∼ N(2.5, 2)
Similarly to α, we chose a normal distribution for γ as well. The mean
was chosen to be 2.5, as based on knowledge from previous experiments
and domain expert’s opinion, we know that the inflection point for LDL
aggregation data of this type is usually around 2.5h. However, in order to
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reflect the high level of uncertainty, we chose a large value for the standard
deviation, in this case σ = 2.
We also set a distribution for the fixed effect γCatB,
γCatB ∼ N(0, 2)
Again, due to lack of information about this fixed effect, we choose a normal
distribution, with mean 0 and a standard deviation 2, which is fairly large,
considering the range of values which the variable time takes.
Similarly for δ,
δfixed ∼ N(0.2, 1)
the normal distribution was chosen. The mean was chosen to be 0.2,
based on past experience, where the slope at the inflection point was around
0.2. Again, the standard deviation was set quite high, in order to reflect the
high level of uncertainty, σ = 1.
3.2 Priors for response distribution parameters
The prior for the shape of the Gamma distribution, chosen as a family dis-
tribution, is assigned, by default by the brms package, to be
shape ∼ Gamma(0.01, 0.01)
Where the first argument is µ - mean, and the second one is the shape.
Again, this prior is very vague, but it is assigned purely to stabilize the model
to be fitted.
3.3 Priors for the standard deviation of random effects
In this case we have two random effects, one for α and one for γ. As al-
ready mentioned, the distributions declared are for the standard deviations
of the random effects. These are:
sdα1|Pat ∼ N(0, 1000)
Again, this prior is deliberately chosen to be weakly informative, as we
do not have information about this random effect. Since we don’t have any
information, we chose to set the mean to 0, and chose a large value for the
standard deviation to reflect the high level of uncertainty . Similarly, we
chose
sdγ1|Pat ∼ N(0, 2)
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which is again a prior which does not make any strong assumptions, as
we do not have much information about this random effect. The mean is
again 0, and the standard deviation is chosen to be 2. Note that while this is
significantly smaller than the standard deviation for the other random effect,
in the context of the units in which gamma is measured - hours, it is still
quite vague and reflecting the large level of uncertainty.
It is worth pointing out that, since all the priors we chose are weakly in-
formative, the observed data would have a stronger influence on the model.
This is, by setting weakly informative priors we ”let the data speak for itself”.
4. Response distribution family and link-function
Family: Gamma()
Link function: Log-link
The family for the response distribution which is chosen is the Gamma family.
The reason for this is because as mentioned earlier, in Gamma distribution
the variance increases with the mean. This is relevant to our case, as the
uncertainty of the measurements of LDL aggregation grows as the values of
the measurements increase. Hence, this property of the Gamma distribution
adequately reflects the nature of our data. In addition, we also experimented
with the lognormal family, but the resulting model was quite a poor fit to
the data, hence this option was not explored further.
As to the link-function, the log-link was chosen. This link function was
chosen through experimenting. As the predictor resulting from our model
does not have a nice, intuitive interpretation, as it is nonlinear, hence an
experiment resulting in a good model is our strongest argument for using
the log-link in this case. In addition, we experimented with the identity link
function, but this resulted in a model, which did not converge, meaning that
we could not obtain reliable estimates for our model parameters. We also
experimented with the inverse-link function, which yielded results which were
very similar to the case when log-link was used, hence we decided to stick to
the log-link, purely for convenience.
4.4.1.2 Model Evaluation
1. Convergence Diagnostics
As one can see in Appendix A.1.1 all parameters have Rˆ = 1.00, which
suggests that the sampling algorithm has converged to the posterior distri-
bution. In addition, all effective sample sizes are reasonably large, which
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means that it is likely that the samples drawn by the algorithm are reason-
ably close to the posterior distribution.
2. Model Checking
In order to evaluate the posterior predictive performance of Model 1, first
we are going to compare the distribution of observed values to several sim-
ulations of predicted values, calculated for the same respective values of the
explanatory variables, as discussed in Subsection 4.2.5.1. The corresponding
plot is given below.
Figure 4.4: Distribution of observed values, compared with distributions
of simulated values drawn from the posterior predictive distribution, using
Model 1
As one can see, the dark-blue line, representing the distribution of the ob-
served values, has quite similar shape to the light-blue lines, representing
the distributions of the simulated values drawn from the posterior predictive
distribution. This suggests that the model fitted is doing reasonably well is
posterior prediction.
In addition, we calculate test quantities, discussed in Subsection 4.2.5.1. In
our case we decided to calculate both the test quantity T1 - mean and T2 -
skewness, as these the combination of these two is an adequate way to de-
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scribe a distribution. The skewness function used to obtain this quantity is
known as Pearson’s second coefficient [41], defined as:
Sk2 = 3
(µ− ν)
σ
(40)
where µ - mean, ν - median, and σ - standard deviation. The plot illustrating
these test quantities is given below:
Figure 4.5: Test quantities: A) T1 - mean and B) T2 - skewness for Model1
As one can see, in both cases the values for T1(y) and T2(y) are quite
close to the mean of the distributions, generated from calculating these test
quantities for the simulated values yrep, which suggests that the model per-
formance in terms of posterior predictive power is reasonable.
We now continue to the second model we fitted.
4.4.2 Model 2
4.4.2.1 Model Declaration
1. Model formula
The model formula for this model is the one stated in (32).
2. Fixed and random effects related to parameters
Using the notation of brms, the model parameters are defined as:
α ∼ 1 + 1|Pat/Cat
γ ∼ 1 + 1|Pat/Cat
δ ∼ 1.
This means that there is a fixed effect and two random effects for both α and
γ, and a fixed effect for δ. But before focusing on the priors chosen, let us
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first explain the two random effects.
These are explained in the expression
1|Pat/Cat,
which can be expressed as
1|Pat+ 1|Pat : Cat.
The random effect 1|Pat describes the variation across patients (Pat). In
addition, the random effect 1|Pat : Cat describes variation across the group-
factor of patient (Pat) and its group-levels, determined by category (Cat).
We now proceed to discussing the priors.
3. Priors
3.1. Priors for fixed effects
The priors for the fixed effects αfixed, γfixed, and δ are the same as the ones
chosen for Model 1.
3.2. Priors for response distribution parameters
The prior for the shape of the Gamma distribution, which was again chosen
as a family distribution, is, again, assigned by default by the brms package.
3.3 Priors for the standard deviation of random effects
The distributions chosen for the standard deviations sdα1|Pat and sdγ1|Pat are
the same as for Model 1. In addition, however, we also have two more prior
distributions for the standard deviations of the random effects of α and γ,
respectively:
sdα1|Pat:Cat ∼ N(0, 1000)
and
sdγ1|Pat:Cat ∼ N(0, 2)
As one can see, once again we opted for the normal distribution for the priors
of these standard deviations. Again, the reason for this is because we do not
have any concrete prior knowledge about their values. Hence we set up priors
which only reflect our vague idea of the scale of these values, captured mainly
by the standard deviations of these normal distributions. Yet, even though
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very weakly informative, these priors ensure some computational stability, by
imposing some reasonable limits of the search space for the values of interest.
4. Response distribution family and link-function
The response distribution family and the link-function are the same as cho-
sen in Model 1.
4.4.2.2 Model Evaluation
Convergence Diagnostics
As one can see in Appendix A.1.2 all parameters have Rˆ = 1.00, which
suggests that the sampling algorithm has converged to the posterior distri-
bution. In addition, all effective sample sizes are reasonably large, hence, it
is reasonable to assume that the draws of the algorithm are reasonably close
to values drawn from the posterior.
2. Model Checking
In order to evaluate the posterior predictive performance of Model 2, first
we are going to compare the distribution of observed values to simulations of
predicted values, calculated for the same respective values of the explanatory
variables. The corresponding plot is given below.
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Figure 4.6: Distribution of observed values, compared with distributions
of simulated values drawn from the posterior predictive distribution, using
Model 2
As one can see, the dark-blue line, representing the distribution of the ob-
served values has a very similar shape to the light-blue lines, representing the
distributions of the simulated values drawn from the posterior predictive dis-
tribution (for the same respective values of the explanatory variables). This
suggests that the model fitted is doing reasonably well is posterior prediction.
We now calculate the test quantities we calculated for Model 2, T1 - mean
and T2 - skewness. The results are provided in the plot below.
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Figure 4.7: Test quantities: A) T1 - mean and B) T2 - skewness for Model2
As one can see, T1(y) is not as close to the mean of the distribution of
T1(y
rep)-values for Model 2, as it is for Model 1. Still it is reasonably close. In
plot B) T2(y) is very close to the mean of the distribution of T2(y
rep)-values.
Based on both plots, it seems reasonable to assume that Model 2 does fairly
well in posterior prediction.
4.4.3 Model Comparison
Now that we have fit two models which seem to perform well in the poste-
rior predictive checks, we are going to compare them. We are going to use
the Leave-One-Out Cross-Validation, described in Subsection 4.2.5.2, which
evaluates the pointwise out-of-sample prediction performance of the models.
In order to do this comparison, we run a function in brms package which
calculates the approximation of the LOO expected log predictive density
(elpd), using the Pareto-Smoothing Importance Sampling (PSIS), as de-
scribed in Subsection 4.2.5.2. However, as explained earlier, there are cases
in which the log pointwise predictive density (lppd) cannot be adequately ap-
proximated for some data points. If the number of these influential points is
reasonably small, this usually means they are just outliers, which the model
fitted is ”surprised” to encounter. The diagnostic used to determine whether
a point is influential is the pareto-k (kˆ) parameter, as discussed earlier. Points
with pareto-k > 0.7 are considered problematic. We generated pareto-k plots
for both of our models, provided below, provided in Appendix A.2. As one
can see from Figure A.1, Model 1 has 6 influential observations. From Figure
A.2 one can see that Model 2 has 7 influential observations. Thus, we refit
each of the models, retaining one of the influential points at a time. Once
these are refitted, we are able to calculate the elpd for each of the models
and compare them. The output of the comparison is given below.
1 elpd_diff se_diff
2 model2 0.0 0.0
3 model1 -122.0 21.1
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This output means that Model 2 has a higher expected predictive accuracy.
Thus, we choose to use Model 2 for the prediction of the LDL values at
2h-time point.
4.4.4 Performance of Model 2 on a test set.
Now that we established that Model 2 is the better of the two models, in
order to ensure that our predictions of the 2h-values would be reasonable, we
decided to test it on an existing test set. Since we do not have any LDL values
for time point exactly 2h, we decided to test our model on the closest available
ones. For all samples we have a measurement of LDL, taken around time
point t=1.94h, which is very close to 2h. Thus we retained 10 LDL values
measured at t = 1.94h, and then refit Model 2 without them. Then we tested
its predictive performance on these values. The mean absolute error of the
predictions was MAE=0.2386. While it is desirable for this value to be
smaller, it can still be considered reasonable, considering that the data set
used to fit the model is fairly small. We then proceeded to obtaining the
predicted values of LDL at the 2h-time point.
Having obtained these, we now proceed to discussing the results from the
statistical tests we conducted.
Chapter 5
Results
In this section we state the results obtained in this thesis project. The re-
sults, presented below, are given as answers to the main research questions
asked in the thesis, which were stated earlier on in the Introduction section.
Throughout the whole result section, when we talk about LDL values, we
mean the radius of LDL aggregates at time point t = 2h, which we use as a
single quantitative measure of LDL aggregation.
1. Is there a significant difference in LDL aggregation of bariatric
patients before and after the operation?
The LDL aggregation values are obtained for each one of the 56 samples,
by using the fitted LDL aggregation model to predict them. Thus, we have
available 28 before- and 28 after-operation LDL 2h-time point values, which
correspond to the 28 individuals we have data for. We then form differences
between the pairs of values of each patient. The difference is formed in the
direction before minus after values.
In order to establish whether there is a statistically significant difference
between before- and after-operation aggregation of LDL, we use the paired
t-test.
Null Hypothesis: The mean difference between the before-after pairs of
LDL aggregation values is 0.
Significance Level: The significance level we choose for the paired t-test is
the standard in the scientific community, p-value = 0.05.
Checking Assumptions: We assume that the differences of before-after
pairs are independent of each other, as we assume that the measurements
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taken for each person are independent. As to the second assumption of nor-
mal distribution of the differences, we generate the following histogram:
Figure 5.1: Histogram of differences between before and after LDL values at
t=2h
As one can see, the distribution of before-after differences appears to
be roughly normal, which is sufficient, as the paired t-test is fairly robust.
Hence, we proceed to applying the paired t-test to formally test the mean
difference of before-after LDL aggregation. The result is given below.
Result:
The R output of the paired t-test is the following:
1 Paired t-test
2 data: before_ldl and after_ldl
3 t = -0.3815, df = 27, p-value = 0.7058
4 alternative hypothesis: true difference in means is not equal to 0
5 95 percent confidence interval:
6 -90.14508 61.87912
7 sample estimates:
8 mean of the differences
9 -14.13298
As one can see, the sample estimate for the mean of differences
µ = -14.13298, but the p-value = 0.7058, hence, this is not a statistically
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significant result on the 0.05-level. In addition, consistent with the conclu-
sion indicated by the p-value, the 95%-confidence interval contains 0.
Thus we fail to reject the null hypothesis that the mean difference is 0.
2. Are there any significant changes in the structure of LDL par-
ticles of the bariatric patients before and after the operation?
Before we continue with answering this question, let us first discuss what
exactly is asked. In the context of this question ”changes in the structure of
LDL” means changes in the amount of the various lipids of LDL before and
after the operation. Thus, in order to investigate potential changes in the
lipids, we are going to form differences between their before- and after-values.
As already mentioned, the structure of LDL particles can be divided into
a surface and a core. Thus, in order to answer the question, we are going to
separately investigate changes in surface lipids and changes in core lipids. As
we are going to test multiple hypotheses for each of these cases, we are going
to use the Benjamini-Yekutiel multiple comparison adjustment and consider
these as two separate families, respectively - surface-lipids and core-lipids
family of hypotheses.
2.1. Change in Surface Lipids
In order to investigate changes in surface lipids, we form the difference be-
tween the before- and after-operation values for each lipid. We then generate
histograms of the differences between the before and after pairs for each lipid.
For the lipids whose differences appear to follow a roughly normal distribu-
tion, we use paired t-test for formally testing the mean difference between
the before and after values. For the lipids whose differences appear to follow
a clearly non-normal distribution, we use the Wilcoxon signed-rank test for
formally testing whether the median of the differences is 0.
Null Hypotheses: Since the differences of lipids have to be tested with
two different tests, it is worth pointing out that the null hypotheses that are
being tested are different.
• Null Hypothesis for Paired T-test: The mean difference between the
before-after pairs of surface-lipids values is 0.
• Null Hypothesis for Wilcoxon Rank-Order Test: The median of
the differences between the before-after pairs of surface-lipids values is 0.
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Significance Level: The significance level we choose for both the paired
and the Wilcoxon Rank-Order t-test is p-value = 0.05.
False Discovery Rate Level: In order to adjust the results for multi-
ple comparisons, we use the Benjamini-Yekutieli adjustment. The FDR level
chosen is α = 0.1. This value is standard for FDR multiple comparison ad-
justments.
Result: For the sake of brevity, we only provide the results which were
deemed significant after the Benjamini-Yekutieli multiple comparisons ad-
justment. The results are split into two tables - one containing the statisti-
cally significant results obtained from paired t-tests and the other one con-
taining the results obtained from Wilcoxon rank-order tests. It is important
to point out the distinction, as the two tests have different null hypotheses.
The two tables are given below.
Paired T-test Results
Surface Lipid Mean Diff. 95% CI p-value Avg.%
Change
LysoPC18:00 0.1182143 (0.0573, 0.1791) 0.000463 0.067
LysoPC18:02 0.06357143 (0.0194,0.1078) 0.00649 0.2
LysoPCtotal 0.3453571 (0.1357, 0.5550) 0.00222 0.11
PC34:01alkyl -0.06285714 (-0.0893,-0.0364) < 0.0001 0.23
Pcalkyl total -0.3032143 (-0.4880,-0.1185) 0.0023 0.1
PC32:00 -0.1018 (-0.1355,-0.0680) < 0.00001 0.22
PC34:02 1.605 ( 0.7124, 2.4976) 0.001 0.09
PC36:02 1.2593 ( 0.7002, 1.8183) < 0.0001 0.11
PC38:03 0.4025 ( 0.1769,0.6281) 0.001077 0.19
PC40:07 -0.0661 ( -0.0895,-0.0426) 0.00001 0.42
SPHM16:00 -1.0036 ( -1.3852,-0.6219) <0.00001 0.15
SPHM21:00 0.0936 ( 0.0244,0.1628) 0.009893 0.34
SPHM23:00 0.2382143 (0.1508, 0.3256) < 0.00001 0.24
SPHM24:01 -1.4704 (-1.9196,-1.0211) <0.000001 0.28
SPHMtotal -2.5675 ( -3.8045,-1.3305) 0.000223 0.13
Table 5.1: Surface lipids which have a mean difference of before- and after-
operation values, which is different from 0 and statistically significant, mea-
sured by paired t-test
The Average percentage change (Avg. % Change), provided in the table,
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is calculated as the absolute value of the mean difference, divided by the
average value the specific lipid for the before-operation state(given in molar
percentage).
Wilcoxon Signed-Rank T-test Results
Surface Lipid Median Diff. 95% CI p-value
PC36:01alkyl -0.0350 (-0.0501,-0.0150) 0.005186
Pctotal 2.34 (1.095, 3.740) 0.000425
SPHM24:02 -0.57 (-0.92, -0.25) 0.000561
Table 5.2: Surface lipids which have a median of the differences between
before- and after-operation values which is different from 0 and statistically
significant, obtained by Wilcoxon signed-rank test.
The number of rejected null hypotheses before adjusting for multiple com-
parisons was in total 27, but after the adjustment decreased to 18, which is
a significant change.
2.2. Change in Core Lipids
In order to investigate the change in core lipids, we inspected the differ-
ences of the pairs of before- and after-operation values for each lipid. The
null hypothesis, significance level, and FDR level are the same as in Question
2.1. The differences for all core lipids were normally distributed, hence we
used the paired t-test in all cases, in order to formally test the difference.
Initially the core lipids ChoE18:01 and ChoE18:03 were found to have a mean
difference which was different from 0 and statistically significant. However,
after applying the Benjamini-Yekutieli multiple comparisons adjustment with
FDR level α=0.1, none of the results were deemed significant.
3. Are there any significant correlations between LDL aggrega-
tion and LDL structure lipids before and after the operation?
As in the previous question, we needed to investigate correlations between
LDL and surface and core lipids, respectively, by considering them separately.
In all cases considered, the correlation test which was used was the Spear-
man’s correlation test, with p-value < 0.05 chosen as a significance level. The
Benjamini-Yekutieli multiple comparisons adjustment was used, with FDR
level α=0.1 in all cases.
3.1. Correlations between LDL Aggregation and Surface Lipids
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In order to answer this question, we considered separately the pair of before-
operation values for LDL and the surface lipids, and the pair of after-operation
values, respectively. The reason why we could not look into a correlation of
all LDL values (both before- and after-) and all values of each lipids, was
because the before- and after-values for LDL, as well as for all lipids, are
correlated. They are correlated because each before-after pair corresponds
to the same patient, thus violating the independence-of-observations assump-
tion, required when calculating correlations.
We split the hypotheses tested to Before-correlations and After-correlations
families, respectively. We applied the Benjamini-Yekutieli adjustment to the
p-values obtained from the Spearman correlation tests.
a) Correlations between Before-values for LDL and Before-Values
for Surface Lipids
The initial test results suggested that the lipids LysoPC16:00, LysoPC20:04,
as well as the total sum of the molar percentages of all LysoPC-lipids (LysoPC-
Total) for each patient, had a statistically significant correlation with the
before-values of LDL. However, after applying the multiple comparisons ad-
justment, none of these results were deemed statistically significant.
b) Correlations between After-values for LDL and After-Values
for Surface Lipids
In this case, the initial test results suggested that the after-values lipids
PC36:02alkyl, PC36:02, LysoPC18:02, PC38:04, PC36:04, PC34:02, PC38:06,
PC34:01alkyl, PC34:02alkyl had a statistically significant correlation with
the after-values of LDL aggregation. However, after applying the multiple
comparisons adjustment, none of these were deemed significant.
3.2. Correlations between LDL Aggregation and Core Lipids
The core lipids were split in the same way as the surface lipids above. The
hypotheses were split into a Before-correlations and After-correlations fami-
lies. The FDR level for Benjamini-Yekutieli adjustment and the p-value level
of statistical significance were also as above.
a) Correlations between Before-values for LDL and Before-Values
for Core Lipids
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None of the correlations between before-values of LDL and before-values
of core lipids were deemed statistically significant, both before and after ad-
justing for multiple comparisons.
b) Correlations between After-values for LDL and After-Values
for Core Lipids
The initial test results suggested a statistically significant correlation be-
tween the after-values of LDL and the after-values of the lipid ChoE20:04.
However, after adjusting for multiple comparisons, none of the results were
deemed statistically significant.
4. Are there any significant changes in the clinical parameters
of the bariatric patients before and after the operation?
As in the previous question, in this context, ”significant changes in clinical
parameters” means statistically significant changes in before- and after-values
of the clinical parameters. As before, in order to investigate these changes,
we formed the differences between the pairs of values for each clinical param-
eter and visually inspected their normality using histograms. The change in
clinical parameters whose differences were normally distributed was tested
using the paired t-test. For the ones with non-normal distribution we used
the Wilcoxon signed-rank test. The null hypotheses, significance level, and
FDR level are the same as in Question 2.
As done previously, we spilt the results into two tables. The first table con-
tains the clinical parameters whose mean difference is statistically significant
from 0, evaluated with the paired t-test. The second table contains the clini-
cal parameters whose median of the differences is statistically significant from
0, evaluated with the Wilcoxon signed-rank test.
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Paired T-test Results
Surface Lipid Mean Diff. 95% CI p-value Avg.%
Change
RRDiast(Mean) 4.8 (1.86,7.74) 0.0024 0.06
ogtt0 0.67 (0.25,1.09) 0.0029 0.10
ogtt60 2.33 (1.08,3.58) 0.0008 0.26
ogtt120 3.53 (2.34, 4.73) < 0.00001 0.44
HbA1C 3.21 ( 0.63, 5.81) < 0.01682 0.08
Table 5.3: Clinical parameters which have a mean difference of before- and
after-operation values that is different from 0 and statistically significant,
measured by paired t-test
Wilcoxon Signed-Rank Test Results
Clinical Parameter Median Diff. 95% CI p-value
Weight 25.55 (23.4, 28.7) < 0.00001
BMI 9.06 ( 8.24, 10.33) < 0.000001
Pulse (Mean) 10.00 (5.50, 13.75) 0.00023
ogtt30 -1.75 ( -3.35, -0.70) 0.00225
Table 5.4: Clinical parameters which have a median of the differences between
before- and after-operation values, which is different from 0 and statistically
significant, obtained by Wilcoxon signed-rank test.
5. Are there any significant correlations between LDL aggregation
and clinical parameters before and after the operation?
Similarly to the previous questions, in order to investigate the correlations
of LDL aggregation and clinical parameters, we split them into before- and
after-values. As before, we have two families of hypotheses to test - before
and after-correlations, respectively. In order to investigate the correlations,
the Spearman’s correlation test was used, with p-value < 0.05. The FDR
level for the multiple comparisons adjustment used α=0.1.
5.1. Correlations between Before-values for LDL and Before-Values
for Clinical Parameters
None of the tests deemed a statistically significant correlation between before-
values of LDL and clinical parameters, neither before, nor after adjusting for
multiple comparisons.
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5.2. Correlations between After-values for LDL and After-Values
for Clinical Parameters
In this case, the initial tests deemed the correlation between the after-values
of LDL and the after-values of the clinical parameter ogtt0 (Oral glucose
tolerance-insulin releasing test value at t=0h) to be statistically significant.
However, after applying the multiple comparisons adjustment, none of the
results were deemed significant.
6. Are there any significant correlations between change in LDL
aggregation, LDL structural lipids and clinical parameters as a re-
sult of bariatric surgery?
In order to answer this question, we first formed the differences between
pairs of before-after values for LDL, surface lipids, core lipids, and clinical
parameters. Once this was done, we then used Spearman’s correlation test
to evaluate the correlations, with significance level of 0.05. As before, the hy-
potheses we tested were split into three families - surface-lipids, core-lipids,
and clinical-parameters family, respectively. Benjamini-Yekutieli multiple
comparisons adjustment with FDR rate α=0.1 was applied to each family.
6.1. Correlations of change in LDL with change in surface lipids
The initial test results yielded a statistically significant correlation between
the change in LDL and the change in PC36:02alkyl. However, after apply-
ing the Benjamini-Yekutieli multiple comparisons adjustment, none of the
results were deemed statistically significant.
6.2. Correlations of change in LDL with change in core lipids
None of the correlations between change in LDL and change in core lipids
were deemed statistically significant, neither before, nor after adjusting for
multiple comparisons.
6.3. Correlations of change in LDL with change in clinical pa-
rameters
None of the correlations between change in LDL and change in clinical param-
eters were deemed statistically significant, neither before, nor after adjusting
for multiple comparisons.
Chapter 6
Discussion
In this thesis we studied the change of LDL aggregation in bariatric patients
before and after the surgery. In addition, we studied the changes in the LDL
lipidome and clinical parameters of the patients pre- and post operation.
We also briefly discussed potential correlations of LDL aggregation with the
lipidome and clinical measurements.
We established that there was no statistically significant difference be-
tween the before- and after-operation LDL aggregation (where LDL aggre-
gation was described by LDL radius at time t=2h). This result suggests that
bariatric surgery does not seem to significantly influence LDL aggregation.
In addition, we established that there were significant changes in surface
lipids, both before and after multiple comparisons adjustment. The changes
mainly occurred in lipids from the Lysophosphatidylcholine (LysoPC), Phos-
phatidylcholine (PC), and Sphingomyelin (SPH) groups. As to the core lipids,
there were two lipids which exhibited statistically significant difference in
before- and after-operation values. However, after adjusting for multiple
comparisons, these were deemed insignificant. Thus, bariatric surgery ap-
pears to contribute to change in the surface of LDL particles, but does not
seem to contribute to change in the core.
Furthermore, we investigated the potential correlations between LDL ag-
gregation and lipids in the surface and core of LDL particles both in before-
and after-operation states.
The initial results yielded several statistically significant correlations between
LDL aggregation and surface lipids in both before- and after-operation states.
However, after these were adjusted for multiple comparisons, none of the cor-
relations were deemed statistically significant.
It is worth pointing out that in the original study by Ruuth et al correla-
tions between LDL aggregation and surface lipids were also studied for two
different cohorts. However, none of the initial statistically significant corre-
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lations between LDL aggregation and specific surface lipids in our study, in
both before- and after-states, coincided with the results from the Ruuth et
al study.
As to the core lipids, in the initial results one correlation between a core
lipid and LDL aggregation in the after-operation state was found to be sig-
nificant. However, after multiple comparisons adjustment none of the results
were deemed significant. Thus LDL aggregation does not appear to be cor-
related neither to the surface nor the core structure of the particle in either
of the two states.
We then investigated statistically significant changes in the clinical pa-
rameters of the patients before and after the operation. Nine out of ten of
these clinical factors yielded exhibited statistically significant changes, both
before and after multiple comparisons adjustment. Our findings suggested
that bariatric surgery appears to contribute to lowering of diastolic blood
pressure, pulse, as well as glucose level (in the context of the oral glucose
test) in all but one case - at ogtt30, where the glucose level appeared to be
higher after the operation. In addition, it appears that a bariatric surgery
might contribute towards lowering of the average glucose level, HbA1C. Un-
surprisingly, bariatric surgery appears to also lower the weight and BMI of
the patients.
Additionally, correlations between LDL aggregation and clinical param-
eters in both before- and after-operation states were investigated. In the
initial results, a statistically significant correlation between LDL and the
ogtt0 variable was found in the after-operation state, however, after multiple
comparisons adjustment none of the results were deemed significant. Thus,
LDL aggregation does not appear to be correlated to the clinical parameters
of the patients neither in before-, nor after-operation state.
Lastly, we investigated the correlations between change in LDL aggre-
gation, change in the lipids in the LDL lipidome and clinical parameters.
In the initial test results, there was only one surface lipid - PC36:02alkyl,
whose change was significantly correlated with the change in LDL aggrega-
tion. However, after multiple comparisons adjustment none of the correla-
tions were deemed statistically significant. Thus, bariatric surgery does not
seem to induce any simultaneous change of LDL aggregation, lipids from the
LDL lipidome, and clinical parameters.
Having discussed the results, it is now worth looking more closely into our
methodology and suggest some improvements to be done in the future.
To start with, the LDL aggregation dataset we used to fit our model, was
fairly small - 28 subjects, 56 samples - before- and after-operation sample
for each subject, 368 points in total. A potential improvement for a future
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study would be to obtain a dataset with a larger number of subjects tested.
In addition, each sample contained on average around 7 points, representing
LDL size at a certain time point. In a future study the number of data points
per sample should be increased by measuring the LDL size at smaller time
intervals, which would potentially result in creating a more accurate model,
decreasing the MAE for predictions.
In addition, we used data points of LDL sizes up to 1500nm, when it
is recommended to only use measurements up to 1000nm. If measurements
are taken at shorter intervals, this would allow for obtaining a reasonable
number of data points with value less than 1000nm. Since the uncertainty
around these is considered to be smaller, we can use them to fit a potentially
more accurate model. This however raises another question. As mentioned
earlier, the upper asymptote for curves fit to aggregation values of LDL, is
around 3000nm. One could ask whether using a set of values only up to
1000nm to fit such a curve is reasonable. Thus a logical suggestion would be
to look into alternative models to fit to data points up to 1000nm. Since the
1000nm-value for most samples lies at the part of the Richard’s curve which
is concave upward, one possible suggestion would be to try and model LDL
aggregation using exponential growth.
Lastly, while the final model selected for modelling LDL aggregation per-
forms reasonably well in prediction, it could be improved. One way this could
be done is by finding more informative prior distributions for the parame-
ters.
Chapter 7
Conclusions
In this thesis we focused on studying LDL aggregation in bariatric surgery
patients. The goal of the thesis was to investigate whether LDL aggregation,
the structure of LDL, and clinical parameters of patients change significantly
after the operation. In addition, we investigated potential correlations of LDL
aggregation with lipids in the LDL lipidome and clinical parameters.
The main task in the thesis was to model LDL aggregation and obtain
a single quantitative measure for it - in this case, the size of LDL at the
2h time point. After obtaining the predictions for this time point, we con-
ducted statistical tests, in order to answer the research questions about LDL
aggregation.
We discovered that undergoing bariatric surgery does not seem to result
in significant changes of LDL aggregation in patients. However, it appears
to result in changes in the surface of LDL, as well as significant improvement
of blood pressure, glucose level and, unsurprisingly, BMI. In addition, LDL
aggregation in bariatric surgery patients does not seem to be significantly
correlated to the structure of LDL or clinical parameters before or after the
operation.
Furthermore, bariatric surgery does not appear to induce any simultaneous
changes of LDL aggregation and its structure or clinical parameters of the
patients.
This thesis project was based on a fairly small cohort, so replicating the
conducted research on data from more subjects could be seen as a logical
continuation. Nevertheless, our findings bring us one step closer to revealing
the secrets of LDL aggregation and the ultimate goal of making the diagnosis
and control of coronary artery disease more reliable and efficient.
80
Bibliography
[1] NHLBI. High blood cholesterol. webpage. https://www.nhlbi.nih.
gov/health-topics/high-blood-cholesterol [Accessed 31 Jul. 2019].
[2] Stan Development Team. Effective sample size. web-
page. https://mc-stan.org/docs/2_19/reference-manual/
effective-sample-size-section.html [Accessed 31 Jul. 2019].
[3] Anon. Oral glucose tolerance test. webpage. https://www.diabetes.
co.uk/oral-glucose-tolerance-test.html [Accessed 31 Jul. 2019].
[4] Anon. What is hba1c? webpage. https://www.diabetes.org.uk/
guide-to-diabetes/managing-your-diabetes/hba1c [Accessed 31 Jul.
2019].
[5] Atkinson, A. C. Optimal experimental design. In International En-
cyclopedia of the Social Behavioral Sciences, 2 ed. 2015.
[6] Benjamini, Y., and Yekutieli, D. The control of the false discovery
rate in multiple testing under dependency.
[7] Bhagavan, N., and Ha, C. Essentials of Medical Biochemistry, 2nd
Ed. Academic Press, 2015.
[8] Blanco, A., B. G. Medical Biochemistry. Academic Press, 2017, ch. 3.
[9] Burkner, P.-C. brms: An r package for bayesian multilevel models
using stan. Journal of Statistical Software 80, 1 (2017).
[10] Chang, K.-H. Reliability Analysis. Elsevier India, 2013, pp. 275–357.
[11] Chavez-Sanchez, L., Chavez-Rueda, K., Legorreta-Haquet,
M. V., Montoya-Diaz, E., and Blanco-Favela, F. The innate
immune response mediated by tlrs in atherosclerosis. In Inflammation,
Chronic Diseases and Cancer. IntechOpen, 2012, ch. 3.
81
BIBLIOGRAPHY 82
[12] DA´vis, T. Wyatt customer support - private correspondence. email,
Mar 2019.
[13] DePoy E., L. N. G. Introduction to Research: Understanding and
Applying Multiple Strategies, 5 ed. Elsevier, 2016.
[14] Fantini, J., and Yahi, N. Brain lipids in synaptic function and
neurological disease. Academic Press, 2015, pp. 53–85.
[15] Feingold, K. and Grunfeld, C. Introduction to lipids and lipopro-
teins. ebook, 2018. https://www.ncbi.nlm.nih.gov/books/NBK305896/
[Accessed 31 Jul. 2019].
[16] Ference, B. e. a. Low-density lipoproteins cause atherosclerotic car-
diovascular disease. 1. Evidence from genetic, epidemiologic, and clinical
studies. A consensus statement from the European Atherosclerosis Soci-
ety Consensus Panel. European Heart Journal 38, 32 (2017), 2459–2472.
[17] Gabry, J. Graphical posterior predictive checks using the bayesplot
package. website, 2019. https://cran.r-project.org/web/packages/
bayesplot/vignettes/graphical-ppcs.html [Accessed 2 Aug. 2019].
[18] Gaziano, T., B. A. Growing epidemic of coronary heart disease in
low- and middle-income countries. Current Problems in Cardiology 35,
2 (2010), 72 – 1150.
[19] Gelman, A. Analysis of variance - why is it more important than ever.
The Annals of Statistics 33, 1 (2005), 1 – 53.
[20] Gelman, A., Carlin, J. B., Stern, Vehtari, A. D. D. H. S., and
Rubin, D. B. Bayesian Data Analysis, 3 ed. Chapman and Hall/CRC,
2014.
[21] Gelman, A., J. G. Handbook of Markov Chain Monte Carlo., 1 ed.
Chapman Hall/CRC, 2011, ch. 6.
[22] George, S., and Johnson, J. Atherosclerosis: Molecular and Cellu-
lar Mechanisms. Weinheim: Wiley-VCH-Verl., 2010, ch. 1.3.
[23] Goeman J. J., S. A. Tutorial in biostatistics: multiple hypothesis
testing in genomics. Statistics in Medicine 33, 11 (2014), 1946–1978.
[24] Graphpad. Interpreting results: Wilcoxon signed-rank test. web-
page. https://www.graphpad.com/guides/prism/7/statistics/stat_
interpreting_results_wilcoxon_.htm?toc=0&printWindow [Accessed 31
Jul. 2019].
BIBLIOGRAPHY 83
[25] Grundy, S. M. Obesity, metabolic syndrome, and cardiovascular
disease. The Journal of Clinical Endocrinology Metabolism, 89, 6,
2595aˆ2600.
[26] J., F. Applied Regression Analysis and Generalized Linear Models. Sage,
2015, ch. 15.
[27] Kahilakoski, O.-P. Bayesian regression analysis of sickness absence.
Master’s thesis, Aalto University School of Science and Technology,
2011.
[28] Maymon, G. Stochastic Crack Propagation: Essential Practical As-
pects. Elsevier, ch. 2, pp. 9–18.
[29] McDonald, J. Handbook of Biological Statistics, 3 ed. Sparky House
Publishing, 2014.
[30] NCBI. What is blood pressure and how is it measured? web-
page. https://www.ncbi.nlm.nih.gov/books/NBK279251/ [Accessed 31
Jul. 2019].
[31] NHLBI. Atherosclerosis. webpage. https://www.nhlbi.nih.gov/
health-topics/atherosclerosis [Accessed 31 Jul. 2019].
[32] NIDDK. Definition facts for bariatric surgery. webpage.
https://www.niddk.nih.gov/health-information/weight-management/
bariatric-surgery/definition-facts [Accessed 2 Aug. 2019].
[33] Paar, Anton. The principles of dynamic light scattering
:: Anton paar wiki. webpage. https://wiki.anton-paar.com/
en/the-principles-of-dynamic-light-scattering/ [Accessed 31 Jul.
2019].
[34] Richards, F. A flexible growth function for empirical use. Journal of
Experimental Botany 10, 2, 290–301.
[35] Ruuth, M. e. a. Susceptibility of low-density lipoprotein particles
to aggregate depends on particle lipidome, is modifiable, and asso-
ciates with future cardiovascular deaths. European Heart Journal 39,
27 (2018), 2562–2573.
[36] Stan Development Team. Interfaces. forum. https://discourse.
mc-stan.org/c/interfaces [Accessed 31 Jul. 2019].
BIBLIOGRAPHY 84
[37] Suckow, M. The Laboratory Rabbit, Guinea Pig, Hamster, and Other
Rodents. Elsevier, 2012.
[38] Tampere University of Technology. Bayesian estimation. web-
page. http://www.cs.tut.fi/~hehu/SSP/lecture10.pdf [Accessed 2
Aug. 2019].
[39] Theodoridis, S. Machine Learning. O’Reily, 2015, ch. 2.
[40] Vehtari A., Gelman, A. J. G. Practical bayesian model evaluation
using leave-one-out cross-validation and waic. Statistics and Computing
27, 5 (2017), 1413–1432.
[41] Weisenstein, E. Pearson’s skewness coefficients. web-
page. http://mathworld.wolfram.com/PearsonsSkewnessCoefficients.
html [Accessed 31 Jul. 2019].
[42] Wyatt-Technology. Dynamics user’s guide. webpage.
https://physiology.case.edu/media/eq_manuals/eq_manual_
Dynamics_Users_Guide_M1400_Rev_K.pdf [Accessed 31 Jul. 2019].
[43] Wyatt.com. Dynamic light scattering (dls) and zeta potential
detectors. webpage. https://www.wyatt.com/products/instruments/
dynamic-electrophoretic-light-scattering-detectors.html [Ac-
cessed 31 Jul. 2019].
[44] Wyatt.com. The theory behind dynamic light scatter-
ing (dls). webpage. https://www.wyatt.com/library/theory/
dynamic-light-scattering-theory.html [Accessed 31 Jul. 2019].
Appendix A
Appendix
A.1 Model Output
A.1.1 Output from Model 1
1 summary(model1)
2 Family: gamma
3 Links: mu = log; shape = identity
4 Formula: LDL ~ log (15 + (alpha - 15)/(1 + exp((gamma - Time)/delta)))
5 alpha ~ 1 + Cat + (1 | Pat)
6 gamma ~ 1 + Cat + (1 | Pat)
7 delta ~ 1
8 Data: Data (Number of observations: 368)
9 Samples: 4 chains , each with iter = 5000; warmup = 1000; thin = 1;
10 total post -warmup samples = 16000
11
12 Group -Level Effects:
13 ~Pat (Number of levels: 28)
14 Estimate Est.Error l-95% CI u-95% CI Eff.Sample Rhat
15 sd(alpha_Intercept) 758.03 204.21 439.35 1230.83 5936 1.00
16 sd(gamma_Intercept) 0.16 0.05 0.08 0.26 3461 1.00
17
18 Population -Level Effects:
19 Estimate Est.Error l-95% CI u-95% CI Eff.Sample Rhat
20 alpha_Intercept 1537.57 257.87 1105.89 2111.64 6459 1.00
21 alpha_CatB 174.07 144.22 4.27 514.51 4008 1.00
22 gamma_Intercept 2.37 0.06 2.25 2.50 8699 1.00
23 gamma_CatB 0.08 0.04 0.01 0.18 4168 1.00
24 delta_Intercept 0.27 0.01 0.25 0.29 12127 1.00
25
26 Family Specific Parameters:
27 Estimate Est.Error l-95% CI u-95% CI Eff.Sample Rhat
28 shape 6.81 0.53 5.81 7.89 15535 1.00
29
30 Samples were drawn using sampling(NUTS). For each parameter , Eff.Sample
31 is a crude measure of effective sample size , and Rhat is the potential
32 scale reduction factor on split chains (at convergence , Rhat = 1).
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A.1.2 Output from Model 2
1 Family: gamma
2 Links: mu = log; shape = identity
3 Formula: LDL ~ log (15 + (alpha - 15)/(1 + exp((gamma - Time)/delta)))
4 alpha ~ 1 + (1 | Pat/Cat)
5 gamma ~ 1 + (1 | Pat/Cat)
6 delta ~ 1
7 Data: Data (Number of observations: 368)
8 Samples: 4 chains , each with iter = 5000; warmup = 1000; thin = 1;
9 total post -warmup samples = 16000
10
11 Group -Level Effects:
12 ~Pat (Number of levels: 28)
13 Estimate Est.Error l-95% CI u-95% CI Eff.Sample Rhat
14 sd(alpha_Intercept) 1241.56 389.34 389.35 2004.24 2840 1.00
15 sd(gamma_Intercept) 0.05 0.03 0.00 0.12 3956 1.00
16
17 ~Pat:Cat (Number of levels: 56)
18 Estimate Est.Error l-95% CI u-95% CI Eff.Sample Rhat
19 sd(alpha_Intercept) 1225.42 330.18 674.34 1945.87 2378 1.00
20 sd(gamma_Intercept) 0.07 0.03 0.01 0.12 2195 1.00
21
22 Population -Level Effects:
23 Estimate Est.Error l-95% CI u-95% CI Eff.Sample Rhat
24 alpha_Intercept 2982.67 458.36 2180.91 3972.90 8102 1.00
25 gamma_Intercept 2.64 0.05 2.54 2.74 9394 1.00
26 delta_Intercept 0.28 0.01 0.27 0.30 13005 1.00
27
28 Family Specific Parameters:
29 Estimate Est.Error l-95% CI u-95% CI Eff.Sample Rhat
30 shape 13.74 1.10 11.67 15.95 19207 1.00
31
32 Samples were drawn using sampling(NUTS). For each parameter , Eff.Sample
33 is a crude measure of effective sample size , and Rhat is the potential
34 scale reduction factor on split chains (at convergence , Rhat = 1).
A.2 Pareto-k Diagnostic Plots
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Figure A.1: Pareto-k Diagnostic Plot for Model 1
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Figure A.2: Pareto-k Diagnostic Plot for Model 2
